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Human Retroviruses, HIV and HTLV 




Retroviruses were for many decades well known 
causative agents of leukemias, lymphomas, other 
cancers, or chronic inflammations in various 
animal species. The discovery of the first human 
retrovirus, human T-cell leukemia virus (now 
renamed human T-lymphotropic retrovirus type 
1; HTLV-1) was reported in 1980 (Poiesz et al., 
1981). HTLV-1 was soon identified as the 
causative agent of adult T-cell 
leukemia/lymphoma (ATLL), a rapidly 
progressing cancer of CD4+ T lymphocytes first 
described in southeastern Japan (Takatsuki et al., 
1977). Knowledge gained from HTLV-1 
research was important for the subsequent 
detection of other human retroviruses, first the 
related HTLV-2 (Kalyanaraman et al., 1982). 
Soon thereafter, human immunodeficiency virus 
(HIV)-1 was for the first time isolated from a 
patient with an early stage of the newly 
recognized acquired immunodeficiency 
syndrome (AIDS) (Barre-Sinoussi et al., 1983). 
Two years later, a second AIDS-causing virus, 
HIV-2, was discovered (Clavel et al., 1986a).  
Investigations among nonhuman 
primates showed a wide distribution of viruses 
resembling both the HTLV and, respectively, 
HIV groups of retroviruses. Simian T- 
lymphotropic retrovirus type (STLV)-1 and 
STLV-2, simian counterparts of HTLV-1 and 
HTLV-2, were identified. STLV-3 forms a third 
group of lymphotropic viruses infecting various 
African monkey species. HTLV-3, a counterpart 
of STLV-3 in man, was recently detected in 
African pygmies (Calattini et al., 2005; Wolfe et 
al., 2005; Calattini et al., 2006; Switzer et al., 
2006). A further HTLV forming a fourth group, 
HTLV-4, also has been reported (Wolfe et al., 
2005). Together, these viruses now constitute 
four groups of primate T-lymphotropic 
retroviruses (PTLV-1, -2, -3, -4), with 
representatives in both simians (STLV) and 
humans (HTLV). Similarly, both HIV-1 and 
HIV-2 were shown to originate from primate 
lentiviruses collectively named simian 
immunodeficiency viruses (SIV).  
Other reports of retrovirus infections in 
humans include isolated cases in which foamy 
retroviruses (Switzer et al., 2004), simian type-D 
retrovirus (Lerche et al., 2001) or SIV (Khabbaz 
et al., 1994) were found in humans as a result of 
direct cross-species nosocomial transmission 
from monkeys to caretakers. Transmission of 
such agents through close and repeated exposure 
to wild monkeys, for example in bushmeat 
hunters, also has been reported (Wolfe et al., 
2004). Transmission of animal retroviruses to 
man may not be restricted to viruses of primate 
origin. Of interest are the recent identification of 
a betaretrovirus closely related to mouse 
mammary tumor virus (MMTV) in patients with 
the autoimmune disease primary biliary cirrhosis 
(Mason et al., 2004; Xu et al., 2004) and the 
isolation of an infectious xenotropic murine 
retrovirus (XMRV) in a form of familial prostate 
cancer characterized by homozygosity for a 
reduced activity variant of the antiviral enzyme 
RNase L (Dong et al., 2007; Fan, 2007). On the 
other hand, an earlier claim of a novel human 
retrovirus, has received no follow-up 
confirmation. This relates to the "human 
retrovirus 5" (HRV-5), which now has been 
identified as a rabbit endogenous retrovirus 
contaminant, RERV-H (Griffiths et al., 2002). 
An overview of the currently known exogenous 
human retroviruses and the diseases associated 
with them is shown in Table 1. In addition, the 
question whether endogenous human 
retroviruses might contribute to human 
autoimmune disease like multiple sclerosis, 
Sjogren's syndrome, systemic lupus 
erythematosus and others remains unresolved 
(Perron et al., 2005; Sander et al., 2005).  
Table 1. Overview of retroviruses isolated from humans 
 
Virus Affiliation  Disease associations 
Human immunodeficiency 
viruses types 1 and 2 (HIV-
1, HIV-2) 
Genus lentivirus; primate 
lentiviruses 
Acquired immunodeficiency syndrome (AIDS) 
and related conditions 
Human T-lymphotropic virus 
type 1 (HTLV-1) 
Genus deltaretrovirus; primate T-
lymphotropic retroviruses 
Adult T-cell leukemia/lymphoma (ATLL) 
HTLV-1 associated myelopathy (HAM) / 
tropical spastic paraparesis (TSP) 
Other HTLV-1 associated inflammatory 
disorders 
Human T-lymphotropic virus 
type 2 (HTLV-2) 
Genus deltaretrovirus; primate T-
lymphotropic retroviruses 
Low pathogenicity — cases of HAM/TSP and 
other neurological disorders; inflammatory 
disorders 
Human T-lymphotropic virus 
type 3 (HTLV-3) 
Genus deltaretrovirus; primate T-
lymphotropic retroviruses 
Unknown 
Human T-lymphotropic virus 
type 4 (HTLV-4) 
Genus deltaretrovirus; primate T-
lymphotropic retroviruses 
Unknown 
Human foamy virus (HFV)  Genus spumavirus Nosocomial infection with no known disease 
association 
Simian immunodeficiency 
virus (SIV)  
Genus lentivirus; primate 
lentiviruses 
Nosocomial infection with too short 
observation  
Simian type D retrovirus  Genus deltaretrovirus  Nosocomial infection with too short 
observation  
Mouse mammary tumor virus 
(MMTV)-like 
Genus betaretrovirus Primary biliary cirrhosis? 
Xenotropic murine retrovirus 
(XMRV) 
Genus gammaretrovirus Familial prostate cancer associated with 
reduced RNase L activity? 
   
   
SAFETY PRECAUTIONS, DISINFECTION, 
INJURIES AND POST-EXPOSURE 
PROPHYLAXIS 
For handling of clinical specimens, all 
retroviruses including HIV and HTLV are 
classified as biological agents of moderate risk 
(biosafety level 2). Biosafety level 3 is required 
for all activities involving propagation of 
infectious virus. Since the physical composition 
of the two viruses is similar, the following 
information derived from investigation of HIV-1 
can be largely applied to the HTLVs.  
The risk of laboratory-acquired infection with 
these viruses stems primarily from 
contamination of the hands and mucous 
membranes of the eyes, nose, and mouth by 
infectious blood and other body fluids. There is 
no evidence that HIV or HTLV are transmitted 
by the airborne route. Strict adhesion to the 
safety precautions is paramount in preventing 
nosocomial infections (Anonymous, 1991; 
Collins et al., 1991; Sewell, 1995). Good-quality 
gloves and a protective laboratory gown should 
always be worn and eyes should be protected 
from spills. Disposable unbreakable plasticware 
should be used, never glassware or other sharp 
or breakable objects.  
Spills or contaminations of laboratory surfaces 
must be decontaminated immediately. Whenever 
possible, a type 2 laminar flow biological safety 
cabinet should be used when handling patient 
samples. Centrifuges, including those of 
laboratories that perform only serology, should 
be equipped with sealed buckets. HIV, HTLV 
and other retroviruses are rapidly inactivated by 
detergents and disinfectants that are effective 
against enveloped viruses. Otherwise, at least 
HIV is relatively stable. At autopsy, HIV was 
isolated up to 16.5 days postmortem from 
various tissues (Douceron et al., 1993). 
Suspensions of the virus in protein-containing 
fluids, or dried preparations are also relatively 
stable (Tjotta et al., 1991). At the optimum pH 
of 7.1 the half-life ranged from about 24 hours at 
37°C to no significant loss over 6 months at –
75°C. Drying the virus on a glass surface or 
freezing caused a 5-12 fold and 4-5 fold 
decrease of activity, respectively. The dried 
preparations, however, were about as stable as 
when stored in a buffered solution (Tjotta et al., 
1991). In another study, 1 log10 of inactivation in 
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culture fluid, seawater, sewage, and 
dechlorinated tap water (all sterile and kept at 
16°C in the dark) required 1.3, 1.6, 2.9, and 1.8 
days, respectively. After the first 4 days the 
inactivation became even slower (1 log10 
inactivation after 4.3, 2.6, 5.7, and 4.6 days 
respectively). HIV was more stable than herpes 
simplex virus, but less stable than poliovirus 
(Sattar and Springthorpe, 1991). These data are 
not meant to suggest that HIV transmission 
might occur by exposure to water, for which 
there is absolutely no basis. They should, 
however, make clear that caution is important 
when working with HIV. 
The standard disinfectant recommended for 
contaminated surfaces is a hypochlorite solution 
with a concentration of 0.5% available chlorine 
(5 g/L, 5000 ppm). When working with HIV 
cultures and virus preparations, a higher 
concentration of 1% available chlorine is 
recommended (Anonymous, 1991; Van Bueren 
et al., 1995). Fresh 2% solutions of alkaline 
glutaraldehyde are effective, but care should be 
taken that they are not too dilute or have not 
become stale when used for disinfecting HIV 
associated with organic matter. A solution of 
iodine and detergent (2% Jodopax) will remove 
all detectable HIV-1 activity. In contrast, 70% 
industrial methylated spirit or 70% ethanol is not 
effective in inactivating dried protein-rich spills 
of cell-free or cell-associated HIV within a 
reasonable amount of time; complete 
inactivation requires up to 20 minutes (Tjotta et 
al., 1991; van Bueren et al., 1994). 
The risk of HIV infection following 
percutaneous needle-stick exposure to HIV-
contaminated blood is estimated to be between 
0.13 and 0.5%. It depends on the depth of the 
penetration (relative risk (RR) of percutaneous 
lesions 16.1), visible contamination of the 
penetrating object with blood (RR 5.2), prior use 
for an intravenous or intra-arterial injection (RR 
5.1) and on the disease stage (respectively the 
viral load) of the index patient (RR 6.4) 
(Anonymous, 1995). Needlestick or other 
puncture wounds, cuts, and skin contaminated 
by spills or splashes of specimen material should 
be thoroughly washed with soap and water and 
disinfected with a nonirritating disinfectant. 
Bleeding should be encouraged. In case of 
percutaneous injury or contact of mucous 
membranes or nonintact skin (e.g., exposed skin 
that is chapped, abraded, or afflicted with 
dermatitis) with blood, tissue, or other body 
fluids potentially infectious, an antiretroviral 
postexposure prophylaxis (PEP) should be 
started immediately according to guidelines 
published online 
http://www.hivatis.org/Guidelines/Default.aspx?
MenuItem=Guidelines. Note that these 
recommendations do not apply to HTLV, as 
many of the drugs effective against HIV, 
particularly the protease inhibitors and non-
nucleoside reverse transcriptase inhibitors, are 
ineffective against HTLV. 
 
HUMAN IMMUNODEFICIENCY VIRUSES 
Biology and Epidemiology 
HIV-1 and HIV-2 are members of the genus 
Lentivirus of the Retroviridae family. They are 
enveloped plus-strand RNA viruses, with a 
diameter of about 110 nm. Infectious particles 
(virions) contain two identical copies of single-
stranded RNA of about 9 to 10 kb. These are 
surrounded by structural proteins that form the 
nucleocapsid and the matrix shell, surrounded by 
a lipid envelope derived from the host cell 
membrane. Viral glycoprotein trimers which 
mediate adsorption to and penetration of the host 
cell membrane are inserted in this envelope (Fig. 
1). 
HIV-1, first isolated in 1983 (Barre-Sinoussi et 
al., 1983) and confirmed in the following year as 
being virologically and serologically associated 
with early and late stages of AIDS (Gallo et al., 
1984; Levy et al., 1984; Popovic et al., 1984; 
Sarngadharan et al., 1984; Schupbach et al., 
1984), is the more aggressive virus and 
responsible for the AIDS pandemic (Table 2). 
HIV-2, discovered in 1986 (Clavel et al., 
1986b), is less pathogenic. Rates of heterosexual 
and mother-to-child transmission of HIV-2 are 
low, and latency dominates the clinical picture; 
the virus rarely causes AIDS (Schim van der 
Loeff and Aaby, 1999; Bock and Markovitz, 
2001; Jaffar et al., 2004). 
Table 2. The CDC 93 classification for HIV infections (see also the appendices below) 
 
Clinical Category 





CD4+ Cell Category 
asymptomatic, 
acute (primary) HIV or PGL 




 (≥29 % of lymphocyte 
count) 
A1 B1 C1 
2 200-499/µL 
 (14-28 % of lymphocyte 
count) 
A2 B2 C2 
3 <200/µL 
 (<14 % of lymphocyte 
count) 
A3 B3 C3 
* see appendix "Signs and conditions defining category B" 
** see appendix "Signs and conditions defining category C (AIDS indicator diseases)" 
 
APPENDIX 1: SIGNS AND CONDITIONS DEFINING CATEGORY B 
Symptomactic conditions in an HIV-infected adolescent or adult that are not included among conditions listed in clinical 
category C and that meet at least one of the following criteria 
(i) attributed to HIV infection or indicative of a defect in cell-mediated immunity 
(ii) conisidered by physicians to have a clinical course or to require management that is complicated by HIV infection 
For example: 
• Bacillary angiomatosis 
• Candidiasis, oropharyngeal (thrush) 
• Candidiasis, vulvovaginal; persistent, frequent, or poorly responsive to therapy 
• Cervical dysplasia (moderate or severe)/cervical carcinoma in situ 
• Constitutional symptoms, such as fever (38.5° C) or diarrhea for>1 month 
• Hairy leukoplakia, oral 
• Herpes zoster (shingles), involving at least two distinct episodes or >1 dermatome 
• Idiopathic thrombocytopenic purpura 
• Listeriosis 
• Pelvic inflammatory disease, particularly if complicated by tubo-ovarian abscess 
• Peripheral neuropathy 
 
 
APPENDIX 2: SIGNS AND CONDITIONS DEFINING CATEGORY C (AIDS INDICATOR DISEASES) 
• Candidiasis of bronchi, trachea, or lungs 
• Candidiasis, esophageal 
• Cervical cancer, invasive (added in the 1993 expansion of the AIDS surveillance case definition). 
• Coccidioisomycosis, disseminated or extrapulmonary 
• Cryptococcosis, extrapulmonary 
• Cryptosporidiosis, chronic intestinal (>1-month duration) 
• Cytomegalovirus disease (other than liver, spleen, or nodes) 
• Cytomegalovirus retinitis (with loss of vision) 
• Encephalopathy, HIV related 
• Herpes simplex: chronic ulcer(s)(>1-month duration); or bronchitis, pneumonitis, or esophagitis 
• Histoplasmosis, disseminated or extrapulmonary 
• Isosporiasis, chronic intestinal (>1-month duration) 
• Kaposi's sarcoma 
• Lymphoma, Burkitt's (or equivalent term) 
• Lymphoma, immunoblastic (or equivalent term) 
• Lymphoma, primary, of brain 
• Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary 
• Mycobacterium tuberculosis, any site (pulmonary [added in 1993] or extrapulmonary) 
• Mycobacterium , other species or unidentified species, disseminated or extrapulmonary 
• Pneumocystis jiroveci (carinii) pneumonia 
• Pneumonia, recurrent (added in 1993) 
• Progressive multifocal leukoencephalopathy 
• Salmonella septicemia, recurrent 
• Toxoplasmosis of brain 




Origin of HIV 
A group of related viruses, SIV, naturally infect 
various species of Old World monkeys and the 
chimpanzee (Fig. 2A). These primate 
lentiviruses are categorized into five major 
lineages. Lineage 1 contains the various isolates 
of HIV-1, which are subclassified into three 
groups, M (main), O (outlier), and N (Simon et 
al., 1998). From the phylogenetic tree it is 
evident that group M isolates (e.g. HIV-1/LAI) 
are more closely related to two isolates from 
chimpanzee, SIVcpzGAB1 and SIVcpzUS, than 
to isolates of HIV-1 group O (HIV-1/ANT70) or 
to another chimpanzee isolate, SIVcpzANT. 
These data indicate that the HIV-1 epidemic is 
the result of zoonotic virus transmissions from 
chimpanzee, subspecies Pan troglodytes 
troglodytes, to human (Gao et al., 1999). The 
origin of group M diversification, i.e., the 
beginning of the HIV-1 pandemic, is placed 
around 1930 (Korber et al., 2000; Salemi et al., 
2001). Recent investigations involving HIV 
serology and RT-PCR performed on fecal 
samples collected in big ape habitats in 
Cameroon have demonstrated a wide variety of 
SIVcpz isolates, which are organized in 
phylogenetic clades restricted to the respective 
habitat area. SIVcpz prevalence in some habitat 
areas is as high as 23 — 35%, while in others it 
is only a few percent or absent. Phylogenetic 
analysis of SIVcpz together with HIV-1 isolates 
clearly shows that HIV-1 group M originates 
from SIVcpz isolates that are prevalent in two P. 
t. troglodytes populations living in the extreme 
south-east of Cameroon. Moreover, HIV-1 
group N originated from SIVcpz isolates from P. 
t. troglodytes living in a different area located 
about 250 km to the west-northwest (Keele et 
al., 2006). Wild chimpanzees therefore act as a 
reservoir for HIV-1 groups M and N. Viruses 
closely related to HIV-1 group O have been 
isolated from gorillas living in forest habitats of 
Cameroon 400 km apart from each other (Van 
Heuverswyn et al., 2006). Phylogenetic analysis 
demonstrates that both HIV-1 group O and 
SIVgor have originated from chimpanzee 
viruses (Fig. 2 B). Whether chimpanzees 
transmitted HIV-1 group O viruses to gorillas 
and humans independently, or to gorillas that 
then transmitted it to humans secondarily is 
unknown.  
Lineage 2 of primate lentiviruses contains the 
various isolates of HIV-2, which are related to 
viruses infecting sooty mangabeys (SIVsm). 
SIVsm also has been transmitted naturally to 
macaques. HIV-2 strain ROD differs less from 
SIVsm or SIVmac than it does from another 
human isolate, HIV-2/EHO (Fig. 2A). This, 
together with other similar examples, has led to 
the conclusion that the HIV-2 epidemic is also 
the result of multiple simian-to-human cross-
species transmissions. Transmission of the 
epidemic subtypes HIV-2 A and B may have 
occurred around 1940 (Lemey et al., 2003). 
 
HIV Groups and Subtypes 
The extraordinary variability of HIV, due to 
rapid mutation and recombination, has led to the 
development and geographical distribution of 
various distinctive clades, or subtypes, of viruses 
(McCutchan, 2000; Peeters and Sharp, 2000). 
HIV-1 group M is divided into subtypes A, B, C, 
D, F, G, H, J and K. Genetic variation within a 
subtype can be of the order of 15–20%, whereas 
variation between subtypes is approximately 25–
35%, depending on the subtypes and genome 
regions examined (Korber et al., 2001). Viral 
recombination, a consequence of infection in a 
person by more than one virus (co-infection or 
superinfection), has furthermore resulted in a 
great variety of so-called circulating 
recombinant forms (CRFs), which increasingly 
dominate the epidemic. To date, more than 20 
CRFs have been defined, as based on their 
identification in at least three epidemiologically 
unlinked individuals and characterization of the 
full-length sequence. According to a WHO study 
involving 23,874 HIV-1 samples from 70 
countries, subtype C accounted for 50% of all 
infections worldwide in 2004. Subtypes A, B, D 
and G accounted for 12%, 10%, 3% and 6%, 
respectively. Subtypes F, H, J and K together 
accounted for 1%. The circulating recombinant 
forms CRF01_AE and CRF02_AG each were 
responsible for 5%, and CRF03_AB for 0.1%. 
Other recombinants accounted for the remaining 
8% of infections. All recombinant forms 
together were responsible for 18% of infections 
(Hemelaar et al., 2006). Isolates of group O, 
which are almost exclusively restricted to 
persons originating from Cameroon, Gabon and 
Equatorial Guinea, differ as much from each 
other as do viruses from different subtypes of 
group M, but their limited number has so far 
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precluded a definition of distinct subtypes. 
Group N viruses were isolated from only a few 
individuals from Cameroon (Simon et al., 1998). 
A total of 7 subtypes of HIV-2, two of which are 
epidemic (A and B) and five non-epidemic (C to 
G), have been defined, resulting from as many 
different simian-to-human transmissions (Lemey 
et al., 2003). 
 
 
FIGURE 1 HIV replication cycle. (A) Overview. (B) Reverse transcription. The retroviral genome contained in virions consists 
of RNA. Its characteristic features include terminal repeats (R), U5 (5' untranslated), U3 (3' untranslated), 3' polyadenylation, a 
binding site for a tRNA which serves as the primer for reverse transcription, and the encapsidation signal Y. During reverse 
transcription, the viral RNA is reverse transcribed into double-stranded DNA and terminal sequences are partially duplicated in a 
way that leads to an LTR composed of U3-R-U5. (C) Unintegrated circular DNA is a short-lived by-product of provirus 
integration; its presence in a cell sample indicates actively replicating virus. (D) Genomic organization of HIV-1 and HIV-2. The 
hatched boxes denote ORFs for proteins which are contained in particles. Drawing modified from (Schüpbach, 2003). 
Of all HIV-1 infections worldwide, 64% are 
present in sub-Saharan Africa. In 2004, 56% of 
infections in that region were caused by subtype 
C, with smaller proportions caused by subtypes 
A (14%) or G (10%), CRF02_AG (7%) and 
other recombinants (9%). Subtype C accounts 
for more than 97% of the infections in Southern 
Africa, Ethiopia and India and for significant 
proportions in East, North and Central Africa. 
Subtype A is responsible for one-third of the 
infections in East and Central Africa, one-fifth 
in West Africa, and 80% in Eastern Europe and 
Central Asia. Subtype B, until two decades ago 
solely responsible for the epidemic in North 
America, the Caribbean, Latin America, Europe 
and Australia, now has a share of 75 to 95% in 
these regions. Subtype D accounts for 10-15% 
of infections in Central and East Africa and 
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about half of those in North Africa. Subtype G 
accounts for one-third of infections in West 
Africa and above 10% in Central Africa. 
Subtypes F, H, J and K have remained minority 
populations in all world regions (Hemelaar et al., 
2006). In contrast, the recombinant forms are of 
increasing relevance. CRF01_AE and 
CRF02_AG are causing heterosexual epidemics 
in Asia and West Africa, respectively. 
CRF01_AE is responsible for 85% of the 
infections in South and South-East Asia and 
16% in East Asia. CRF02_AG accounts for one-
third of new infections in West Africa and about 
6.7% in Central Africa (Njai et al., 2006). Non-
B subtypes account for an increasing proportion 
of newly diagnosed HIV-1 infections in Europe 
(Böni et al., 1999; Lot et al., 2004).  
 
The HIV Replication Cycle 
An overview of HIV replication is given in Fig. 
1A. Like all retroviruses, HIV particles contain a 
characteristic enzyme, reverse transcriptase 
(RT). The enzyme is cleaved, and thereby 
activated, from a precursor protein by the action 
of another retroviral enzyme, the viral protease 
(PR). RT possesses three distinct enzymatic 
functions. It acts as an RNA-dependent DNA 
polymerase (the RT activity in the strict sense of 
the word), an RNase H, and a DNA-dependent 
DNA polymerase. After infection of a host cell, 
these different RT functions serve in turn to 
synthesize a cDNA of the viral RNA, to degrade 
RNA from the cDNA-RNA heteroduplex, and to 
duplicate the cDNA strand. Regulatory 
sequences present at both ends of the viral RNA 
(R-U5 at the 5' end and, respectively, U3-R at 
the 3' end) are thereby complemented and 
partially duplicated in a manner that yields the 
long terminal repeats (LTR). These contain U3-
R-U5 and are located at both ends of the double-
stranded viral DNA (Fig. 1B). This double-
stranded DNA, associated with the proteins of 
the preintegration complex, migrates into the 
nucleus, where it is integrated into the host cell 
genome by a third retroviral enzyme, the 
integrase (IN). The integrated retroviral DNA 
genome is called the provirus. A short-lived 
byproduct of replication, unintegrated circular 
DNA which contains one or two LTRs, has been 
used as a marker for ongoing viral replication in 
patients receiving effective long-term 
antiretroviral combination treatment (Pauza et 
al., 1994; Furtado et al., 1999) (Fig. 1C). 
 
 
FIGURE 2 Origin of HIV-1 and and HIV-2. (A) Phylogenetic tree of primate lentiviruses, derived from Pol protein 
sequences. Numbers 1 to 5 indicate the five major lineages. HIV-1/U455 is a group M, subtype A isolate. ELI is of group M 
subtype D, and LAI is of roup M subtype B. ANT70 and MVP5180 represent group O, and YBF30 is group N. ROD and 
EHO represent different subtypes of HIV-2. SIVcpzGAB1, SIVcpzUS, and SIVcpzANT are chimpanzee isolates, mnd, 
mandrill; agm, African green monkey; syk, Sykes' monkey; sm, sooty mangabey. The bar at the bottom denotes genomic 
diversity. (B) Phylogetic tree showing the relationship of HIV-1 groups M, N and O to chimpanzee and, respectively, gorilla 
lentiviruses (gor). Combined and modified from references (Sharp et al., 1994; Gao et al., 1999) and (Van Heuverswyn et 
al., 2006). 
The genomic organization of HIV-1 and 
HIV-2 proviruses is shown in Fig. 1D. 
Like all retroviruses, HIVs possess the 
open reading frames (ORFs) gag and env, 
which code for structural proteins, 
namely, the precursor proteins of the viral 
capsid and the envelope, and pol, which 
codes for the enzymes. Additional 
overlapping ORFs code for the trans-acting 
transcriptional activator (Tat) and the 
regulator of viral expression (Rev), which are 
both essential for virus replication. 
Furthermore, both HIV types contain ORFs 
for several accessory or auxiliary proteins 
including (in HIV-1) Vif, Vpr, Vpu, and Nef 




FIGURE 3 Translational products of HIV-1 and particle composition. (A) Translation. The open boxes in the genome 
representation at the top denote ORFs of the accessory proteins Tat, Rev, Nef, Vif, Vpr, and Vpu, which are translated into 
proteins of final size. The hatched boxes denote ORFs translated into precursor proteins. The products of the gag, pol, and env 
genes are synthesized as polyprotein precursors. The principal Gag precursor, Pr55Gag, is cleaved by the viral protease (PR or 
p10) into the matrix (MA) protein p17, the capsid (CA) protein p24, and a C-terminal protein p15, which is subsequently cleaved 
into p7 and the nucleocapsid (NC) protein p9. Cleavage of Pr160Gag-Pol, which is produced by ribosomal frameshifting at the gag-
pol junction, yields PR, RT, and IN. All three enzymes remain dimerized after cleavage. RT first forms a homodimer, p66-p66, 
which is subsequently modified into the heterodimer, p66-p51. The Env precursor gp160 is glycosylated in the Golgi system, 
oligomerizes into dimers and trimers, and is cleaved by a cellular protease into the SU protein gp120 and the smaller TM protein 




Virus Entry into Host Cells  
For infection of a host cell, the virion must bind 
via gp120 to a membrane-located virus receptor, 
which is the CD4 molecule. Each monomer of 
gp120 contains a binding site for CD4. Some 
cell types targeted by HIV in vivo express high 
levels of CD4 (for example, T-cells), others, like 
macrophages and dendritic cells (DC), express 
very little. In these instances, HIV may initially 
attach to cells by CD4-independent mechanims 
including interaction of sugar groups on gp120 
with other sugars or lectin-like domains on cell 
surface receptors. Furthermore, cell surface 
proteins with high affinity to gp120 are 
expressed on certain DC populations (DC-
SIGN) and on endothelial cells (DC-SIGNR). 
Gp120 also binds the glycolipid 
galactocerebroside and its sulphated derivative, 
sulphatide. These molecules are expressed on 
neurons and glia in the brain, colon epithelial 
cells and macrophages. In all instances, 
interaction of gp120 with CD4 is, however, 
needed to induce conformational changes in the 
gp120 trimer that enable interaction with a 
coreceptor, a molecule of the family of seven- 
transmembrane chemokine receptors. This 
interaction is followed by another 
conformational change of gp120 allowing 
insertion of the fusion domain of the virion's 
transmembrane protein, gp41, into the host cell 
membrane. This leads to fusion of the viral and 
cellular membranes and viral entry (reviewed by 
Clapham and McKnight, 2002; Moore et al., 
2004). 
The chemokine coreceptors are G-protein-
coupled signaling receptors which bind 
chemokines involved in controlling the 
activation of various leukocytes and their 
migration to a site of infection. In vivo, HIV 
replication is restricted to hematopoietic cells 
that express CD4 and CCR5 and/or CXCR4. 
Cells that express CCR5 can be infected by so-
called R5 viruses (previously called 
macrophage-tropic viruses or non-syncytium-
inducing viruses). CCR5-mediated HIV 
infection is inhibited by the natural ligands of 
CCR5, the beta-chemokines RANTES, MIP-1 
alpha, MIP-1 beta, and MCP-2 (Cocchi et al., 
1995) and by a new class of antiretroviral drugs, 
CCR5 antagonists. The main target cells of R5 
viruses in vivo are T-lymphocytes of the 
CD4+CD45RO+ memory cell phenotype and, to 
a lesser degree, CD4+CD45RA+ naive cells. 
Monocytes, various tissue macrophages and 
dendritic cells are also infected by R5 viruses 
(Montaner et al., 2006). Viruses that enter cells 
via CXCR4 are called X4 isolates (Berger et al., 
1998). In contrast to R5 viruses, which only 
infect primary cultures of lymphocytes or 
macrophages but no T-cell lines in vitro, X4 
viruses also infect T-cell lines and were thus 
called T-cell tropic, syncytium-inducing viruses. 
The natural ligand of CXCR4 is the stroma-
derived factor SDF-1 (Bleul et al., 1996; Oberlin 
et al., 1996); new investigational drugs inhibit 
CXCR4-mediated infection. When X4 viruses 
emerge in vivo, their tropism is broader and new 
cell populations are targeted, as CXCR4 
expression is more widespread and predominates 
on naive T-cells. Current data support a model 
where R5 viruses predominate early in the 
asymptomatic phase, before strains able to use 
CXCR4 and often several other coreceptors 
(R5X4++ viruses) emerge (Scarlatti et al., 
1997).  
 
Aspects of HIV Expression  
Host cell activation induces transcription of the 
viral genes from the promoter located in the U3 
region of the 5' LTR (Fig. 1B). HIV 
transcription is enhanced by a number of cellular 
activation factors, and therefore the virus 
replicates better in activated cells (Stevens et al., 
2006). Virus levels consistently increase when 
the immune system is activated, for example by 
infections, or immunogens such as influenza or 
tetanus toxoid vaccines (Lawn, 2004). Virus 
production is also enhanced by certain 
cytokines, namely the proinflammatory 
cytokines tumor necrosis factor (TNF)-α, 
interleukin (IL)-1β, and IL-6 (Hunt, 2007). It has 
been estimated that the total number of virions 
that are produced and released in an untreated 
HIV-1 infected individual is in the order of 1010 
per day (Simon and Ho, 2003). Conversely, the 
immune system is activated by HIV expression 
(Smith, 2006). Inside infected cells, Nef 
activates signal transduction pathways, namely, 
the NF-κB system, thereby enhancing viral 
transcription (DeLuca et al., 1999; Baba, 2006; 
Stevens et al., 2006). Chronic production of viral 
antigens activates lymphocytes of corresponding 
specificity. In addition, the binding of gp120 to 
CD4 nonspecifically activates CD4+ T 
lymphocytes (Misse et al., 2005). This 
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permanent stimulation causes a chronic 
hyperactivation of the immune system, thus 
constituting a vicious cycle leading to new virus 
expression and killing of CD4+ T lymphocytes 
(Fauci, 1993; Lawn et al., 2001). Efficient 
antiretroviral combination therapy decreases the 
levels of viral proteins by blocking new host cell 
infection, thus leading to a near-normal state of 
immune system activation (Autran et al., 1997). 
Unfortunately, this also drives the virus into 
proviral latency, in which it can be attacked 
neither by the immune system nor the therapy, 
which is effective only against replicating virus 
(Marcello, 2006; Stevens et al., 2006).  
 
Sequence Diversity as a Result of RT Errors and 
Recombination 
Retroviral RTs do not possess a proofreading 
activity and thus have a high misincorporation 
rate. Additional errors may occur during 
transcription since RNA polymerase II does not 
proofread either. For the 9.5 kb HIV genome, 
the in vivo error rate is estimated to amount to 
one to three misincorporations per replication 
cycle (Coffin, 1992). Given the high rate of 
virus replication, every single mutation at every 
possible position of the 9.5 kb long genome 
could arise daily. Another mechanism 
contributing to sequence diversity is genomic 
recombination, which may occur after 
coinfection of a cell with two different viruses 
and encapsidation of both viral RNAs in the 
same particle (heterozygosity). Its frequency is 
estimated at 2 to 3 events per viral genome and 
replication cycle (Jetzt et al., 2000; Zhuang et 
al., 2002). Recombination is well documented in 
CRFs of HIV-1, which are evidence of inter-
subtype recombination (see above). 
Recombination may have played a key role in 
the recent evolution of HIV-1, and the 
geographic intermixing of subtypes, which is 
increasing, is likely to foster the emergence of 
an even greater variety of recombinant strains.  
Sequence diversity is manifested not only on the 
level of the pandemic but also in the infected 
individual, in whom it is generated. The rapidity 
with which virus replicates is an important factor 
contributing to the accumulation of virus 
variants. Selective pressure factors, such as the 
local availability of host cell receptors or 
coreceptors, cellular or humoral antiviral 
immune responses, or antiretroviral drugs may 
then act on this pool of variant viruses, 
inhibiting the growth of some variants and 
favoring the replication of others that exhibit a 
better-suited phenotype. The outgrowth of such 
a group of viruses under selection pressure is 
called a quasispecies (Wain-Hobson, 1992). The 
many quasispecies in each patient evolve both in 
time and space. It is estimated that the sequence 
variability in an infected person increases by 
about 1% per year. In a given patient, different 
quasispecies are present at different sites in the 
body, for example, in Langerhans' cells of 
different skin patches (Sala et al., 1994), 
individual microdissected splenic white pulps 
(Cheynier et al., 1994), brain, or genital tract 
(Zhu et al., 1996). 
 
Virus Transmission and Establishment of 
Infection 
HIV is transmitted predominantly by sexual 
intercourse, connatally from mother to child, 
postnatally by breast feeding, or by parenteral 
inoculation. Globally, the most frequent route of 
transmission is by sexual intercourse. The 
probability of HIV-1 transmission per 
unprotected coital act is estimated at 1/10 — 
1/1,600 for male-to-male transmission, at 1/200 
— 2,000 for male-to-female transmission, and at 
1/200 — 10,000 for female-to-male 
transmission. The average risk is 0.5 to 1% for 
one-time injecting drug use, 12 to 50% for 
connatal mother-to-child transmission, 12% for 
breast-feeding, 90% for a contaminated blood 
transfusion, and 0.1 to 1.0% for nosocomial 
transmission (reviewed in Levy, 1997). In 
general, the risk is proportional to the viral load. 
The virus is not transmitted through casual 
contact in household settings, and there is no 
evidence for transmission by nonhuman vectors. 
Sexual transmission is mediated by infectious 
HIV-1 and/or infected cells in semen or mucosal 
secretions. The relative transmissibility of cell-
free versus cell-associated virus is unknown. 
The risk of transmitting or acquiring infection 
varies greatly. Epidemiologic studies indicate 
that transmission is linked to viral shedding, i.e., 
the amount of infectious virus in genital fluids. 
This in turn is linked to the disease stage and is 
highest during acute infection and late-stage 
AIDS (cf. Fig. 5). Effective antiviral therapy can 
reduce HIV-1 shedding in semen and the female 
genital tract to undetectable levels, but virions 
can sometimes be found in semen even when 
they are undetectable in the blood plasma. Thus, 
12 
although some untreated infected individuals 
pose a low transmission risk, others may be 
'super-shedders' and highly infectious. Acutely 
infected individuals pose a particular risk. 
Moreover, other sexually transmitted diseases 
(STDs) have a marked effect on both viral 
shedding and the risk of acquiring HIV-1 
infection (reviewed in Kaul et al., 2007).  
For sexual transmission, virions or infected cells 
must cross the epithelial barriers of the female or 
male genital tract (reviewed in Shattock and 
Moore, 2003; Kaul et al., 2007). The multiple 
layers of stratified squamous epithelium that line 
the most exposed regions of the female and male 
genital mucosa (vagina and ectocervix in 
women; inner foreskin, penile glans and fossa 
navicularis in men) constitute a significant 
physical barrier. It may be transgressed through 
physical breaches or by infection of intra-
epithelial Langerhans cells. The single-layered 
columnar epithelium which lines the endocervix 
is more fragile than the stratified epithelium, 
especially when present as cervical ectopy 
located on the exocervix and exposed directly to 
physical stress. The single-layered rectal 
epithelium likewise provides little protection 
against potential trauma during intercourse, 
facilitating HIV-1 access to the underlying target 
cells and even the systemic circulation. 
Moreover, the rectum, unlike the genital tract, is 
populated with organized lymphoid tissues 
(lymphoid follicles). The epithelium also 
contains specialized M-cells capable of binding 
and presenting HIV-1 to the underlying 
lymphoid tissue. Such physiological and 
anatomical differences could account for the 
greatly increased risk of acquiring HIV-1 
infection during anal intercourse. 
Both the genital and rectal subepithelial stromal 
tissues are densely populated with dendritic 
cells, macrophages and T cells that express CD4, 
CCR5 and, to a lesser extent, CXCR4 and are 
susceptible to HIV-1 infection. Any break in 
epithelial integrity permits virions direct access 
to these target cells, allowing the establishment 
of infection in mucosal sites (Fig. 4). Infection 
of these cells can be detected within 1 h of the 
addition of SIV to the macaque vagina and is 
most commonly observed where the epithelium 
is abraded (reviewed in Miller and Shattock, 
2003). 
The peroral route of infection is involved in the 
many mother-to-child transmissions through 
breast-feeding, but whether the site of actual 
virus transmission is within the oral cavity or in 
the small intestine is unclear (Herzberg et al., 
2006). Oral transmission also has been 
implicated in cases in which the only risk factor 
was receptive oral intercourse (reviewed by 
Campo et al., 2006; Syrjanen, 2006). In 
parenteral infections, the likely primary target 
cells of intravenously inoculated virus consist of 
dendritic cells, which further transmit the virus 
to circulating CD4+ T-cells (Cameron et al., 
2007). 
For the sexual transmission of HIV at mucosal 
surfaces, DC are considered to play an important 
role (reviewed in Teleshova et al., 2003; Wu and 
KewalRamani, 2006). DC include Langerhans 
cells, which are non-migratory, in epithelial and 
mucosal tissues, and immature DC of myeloid 
origin in the submucosa. Upon contact with 
antigen the myeloid DC are activated and 
migrate through the afferent lymphatics to the T 
lymphocyte-rich areas of regional lymph nodes, 
where they present the antigen to T-cells. Tissue 
culture studies have shown that DC can capture 
and transmit HIV to CD4+ T-cells, mainly 
through DC-SIGN, which interacts with gp120 
(Geijtenbeek and van Kooyk, 2003). In vivo, the 
immature DC with the captured HIV migrate to 
lymphoid tissues and transmit the virus to 
activated CD4+ T lymphocytes (Fig. 4).  
The availability of densely packed CD4+ T-cells 
in the absence of an efficient immune response 
in early infection results in large-scale virus 
production within the regional lymphoid tissues. 
As a consequence, free virus and virus-infected 
cells will leave the lymph node by the efferent 
lymphatics to infect lymph node stations further 
downstream and to enter the blood. This leads to 
generalized infection of all organs including the 
central nervous system (CNS). The SIV model 
has shown that this initial propagation is very 
rapid: infection of DC in the lamina propria of 
the vagina and the regional lymph nodes can be 
detected within 2 days, and plasma viremia was 
demonstrated 5 days after inoculation (Spira et 





FIGURE 4 Propagation of HIV from the mucosal entry port to the lymphatics and the bloodstream. 
 
Acute Phase and Chronicity 
Investigations in the SIV model also have shown 
that there is an early, dramatic effect of the virus 
on the immune system located in the 
gastrointestinal tract (Johnson and Kaur, 2005; 
Veazey and Lackner, 2005). The gut-associated 
lymphoid tissue (GALT) harbors the majority of 
the body's lymphocytes compared with the 
peripheral blood, which contains only 2% of 
these cells. It consists of organized lymphoid 
tissue (Peyer's patches and solitary lymphoid 
follicles) as well as large numbers of activated 
memory T lymphocytes diffusely distributed 
throughout both the intestinal lamina propria and 
epithelium. Due to the constant exposure to a 
myriad of food and microbial antigens, a major 
fraction of GALT CD4+ T cells are activated 
and well differentiated with a memory 
phenotype. Furthermore, the gastrointestinal 
mucosa is in a state of constant physiological 
inflammation characterized by high expression 
levels of proinflammatory, HIV-1–stimulatory 
cytokines. During the first few days of infection 
there is a massive infection of CCR5+CD4+ 
memory T lymphocytes by SIV, which results in 
the elimination of 60 to 80% of these cells 
within days (Veazey et al., 1998; Li et al., 2005; 
Mattapallil et al., 2005). As most CCR5+CD4+ 
memory T lymphocytes of the body are located 
in the GALT, this wipes out 30 — 60% of the 
total of these cells, notably without a similar 
manifestation in the blood or the lymph nodes. 
Similar to the SIV model, studies in HIV-1 
infected patients also have shown an early, 
rapid, profound and persistent loss of intestinal 
CCR5+ CD4+ T cells (Brenchley et al., 2004; 
Mehandru et al., 2004). The early elimination of 
CCR5+ CD4+ T cells notably also includes HIV 
specific CD4+ T-cells, which are lacking in 
disease progressors while being preserved in 
both adult and pediatric long-term non-
progressors (Rosenberg et al., 1997; 
Chakraborty et al., 2005). Thus, the first days 
and weeks of the infection may be at least as 
decisive for the destruction of the CD4+ 
memory T-cells, which is the hallmark of AIDS, 
as are the pathogenetic mechanisms during the 
subsequent protracted chronic stage.  
Acute infection is thus the timepoint at which a 
large proportion of memory T helper cells are 
infected and eliminated. A small minority of 
surviving infected CD4+ CD45RO+ T 
lymphocytes (estimated at less than 106 cells) 
remain in, or return to, a stage of non-activation 
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and proviral latency (Chun et al., 1998; Schacker 
et al., 2000). Establishment of proviral latency in 
these long-lived cells is the strategy by which 
HIV has so far resisted all therapeutic 
eradication attempts (Finzi et al., 1997; Wong et 
al., 1997; Finzi et al., 1999).  
Virus production in the lymphatics, notably also 
the GALT, continues during all phases of 
infection (Biberfeld et al., 1986; Cameron et al., 
1987; Tenner-Racz et al., 1988; Embretson et 
al., 1993; Pantaleo et al., 1993). Monocytes and 
macrophages may also be an important source of 
infectious virus, especially after depletion of 
CD4+ T-cells in advanced disease (Orenstein et 
al., 1997; Igarashi et al., 2001). Virus produced 
in the lymphoid tissues interacts with HIV-
specific antibodies, resulting in immune 
complex formation. These complexes then pass 
through the follicular DC network of the 
lymphatics, where they become trapped. 
Trapped virus remains infectious even in the 
presence of neutralizing antibodies and has a 
half-life of about 2 weeks (Heath et al., 1995; 
Simon and Ho, 2003).  
Figure 5 summarizes the virologic and 
immunologic course of acute and chronic HIV 
infection. Hematologic dissemination from the 
regional lymphoid tissue draining the entry port 
leads to infection of all lymphoid tissues in the 
body, notably the GALT. Replication of HIV 
within the lymphatics, which harbor 98% of the 
total number of lymphocytes in the body, causes, 
in the absence of a specific immune response, a 
rapid increase in the production and release of 
viral particles and number of virus-infected 
cells. In the blood, this is manifested as a 
concomitant burst in cell-free or cell-associated 
infectious virus, particle-associated viral RNA, 
p24 antigen, and cell-associated viral RNA or 
DNA (Clark et al., 1991; Daar et al., 1991; 
Graziosi et al., 1993; Piatak et al., 1993; Koup et 
al., 1994). Concentrations of viral RNA in 
plasma may vary widely, from 104 to more than 
107 copies/ml (Schacker et al., 1998). The 
earliest virus population observed following 
HIV transmission is most frequently of the R5 
phenotype and genotypically very homogenous 
(Zhu et al., 1993; Delwart et al., 1994; Zhu et 
al., 1996), even after exposure to an inoculum of 
mixed R5-X4 phenotype (Cornelissen et al., 
1995). The predominance of R5 viruses in early 
HIV infection may be due to selective pressure 
exerted by selective transepithelial transport 
mechanisms like transcytosis (Meng et al., 2002) 
or by DC, which express CCR5 but not CXCR4. 
Transmission of X4 viruses, however, also has 
been demonstrated in about 15% of early 
infections (Roos et al., 1992).  
Severe primary HIV infection is characterized 
by an initial lymphopenia followed by CD8+ T 
lymphocytosis and inversion of the CD4/CD8 
ratio. Subsequently, the CD8+ T-cell count 
gradually returns to normal whereas the 
CD4/CD8 ratio remains inverted because of a 
relatively small number of CD4+ lymphocytes. 
Primary infection is followed by a prolonged 
and severe cellular hyporesponsiveness to both 
mitogens and antigen (Pedersen et al., 1990; 
Sinicco et al., 1990). 
 
FIGURE 5 Virologic and immunologic parameters in the 
typical course of HIV infection.  
 
Virus levels decrease with the onset of the 
antiviral immune response, namely, the 
production of HIV-specific cytotoxic T 
lymphocytes (Koup et al., 1994; Pantaleo et al., 
1994; Connick et al., 1996). During this initial 
cellular response, up to 6% of the CD8+ T-cells 
may represent HIV-specific cytotoxic T 
lymphocytes (Roos et al., 1992; Yang et al., 
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1996; Borrow et al., 1997). Studies of SIV-
infected macaques in which CD8 T-cells were 
temporarily ablated by infusion of a CD8-
specific monoclonal antibody have also 
demonstrated the importance of these cells in 
lowering the viral load in both primary and 
chronic infection (Jin et al., 1999; Schmitz et al., 
1999). Moreover, after seroconversion, antivirus 
antibodies that bind to virus particles and to 
which complement is fixed may increase virus 
retention on follicular DC that carry complement 
receptors at high density and thus can retain 
large quantities of complexed infectious virions 
(Embretson et al., 1993; Pantaleo et al., 1993; 
Heath et al., 1995). In agreement with this, the 
viral RNA load in early HIV infection is high in 
lymphoid tissues but low in plasma (Pantaleo et 
al., 1998). 
After the initial peak, the virion concentrations 
in blood are, at least in some patients, stabilized 
on individually different levels. This so-called 
"set point" or "inflection point" is strongly 
associated with disease outcome (Jurriaans et al., 
1994; Henrard et al., 1995; Mellors et al., 1996; 
Schacker et al., 1998). The set point is the 
equilibrium that results from the interplay of 
viral, host cell, and immunological factors and is 
usually reached within a few months to 1 year of 
infection (Kaufmann et al., 1998; Schacker et 
al., 1998). Viral titers in plasma subsequently 
increase only slowly for a long time, 
corresponding to clinical latency. During this 
time, the CD4+ T-cell count decreases 
continuously at an individually different but 
constant rate. In the lymphatics, there is a 
continuous, progressive destruction of the 
follicular dendritic cell network leading to the 
complete loss of the regular lymph node 
architecture (Fig. 5, bottom). A marked increase 
in the level of viral RNA in plasma is seen in 
advanced immunodeficiency, when the CD4+ T-
cell count has dropped to below 200/µl. This has 
been interpreted as a final complete breakdown 
of the mechanisms that previously maintained a 
certain control of virus replication. The 
destruction of the FDC network may also 
contribute, as it leads to a decreased retention of 
virions; hence, more virus will reach the 
peripheral blood (Fauci, 1993). Frequently, the 
final increase is also preceded by an emergence 
of X4 viruses (Schellekens et al., 1992; Koot et 
al., 1993). 
 
Dynamics of HIV Replication In Vivo  
The availability of antiretroviral drugs which 
interrupt virus replication and experiments 
involving plasmapheresis have permitted 
determination of the dynamics of virus 
replication (reviewed in Simon and Ho, 2003). 
The half-life of virus in plasma is 56 minutes on 
average. To keep the virus concentration in an 
equilibrium, at least 1010 virus particles must be 
produced per day. About 93-99% of the virus in 
the blood plasma of untreated patients originates 
from activated CD4+ T lymphocytes that get 
infected, produce virus and die with a half-life of 
only 0.7 ± 0.2 days (so-called productively 
infected CD4+ T lymphocytes). An additional 1 
- 7% of the virus in plasma originates from 
longer-lived cells (replication in monocytes or 
macrophages, release of surface-bound virus 
from dendritic cells) that have a half-life of 14 ± 
7.5 days. Less than 1% of the virus in plasma is 
produced by latently infected CD4+ T-cells, 
which become activated and then start producing 
virus. This last compartment has a very slow 
decay rate. Its half-life is estimated at 6 - 44 
months (Finzi et al., 1997; Wong et al., 1997; 
Finzi et al., 1999), or it may even not decay at 
all (Siliciano et al., 2003). Eradication of this 
compartment will not be possible without 
measures that activate the virus from its state of 
latency.
Diagnosis of HIV Infection 
The two principal questions in HIV diagnostics 
are whether a person is infected and, if infected, 
how actively the virus is replicating. The 
susceptibility of a patient's virus to antiretroviral 
drugs has emerged as another question of 
eminent practical importance. 
HIV infection can be detected by a variety of 
tests. Assayed virus components include 
proteins, especially p24, which can be measured 
by immunological tests; RT, whose enzymatic 
activity can be detected by functional tests; and 
viral DNA or RNA, which can be identified by 
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molecular tests. Most frequently, however, HIV 
infection is diagnosed by tests that assess 
whether an individual's immune system has 
produced an HIV-specific immune response. 
Since retroviruses are known to establish 
infections that persist for life, demonstration of 
an HIV-specific immune response, if it is 
consistent and directed against various viral 
antigens, can be trusted to reflect ongoing 
infection. Thus, testing for HIV-specific 
antibodies is still the mainstay of HIV 
diagnostics, at least in adults. In infants, only 
testing for virus components allows early 
diagnosis or exclusion of infection.  
The diagnosis of HIV infection relies on 
commercially available test kits. Competition 
among manufacturers and strict evaluation and 
control by regulatory authorities have led to a 
large number of excellent well standardized 
commercial diagnostic products of high 
sensitivity and specificity, which provide a 
continuously high standard of quality. They are 
usually better and yield more consistent results 
than research procedures developed in 
diagnostic laboratories. Good commercial tests 
are therefore strongly recommended. Using 
unregistered tests for screening or for certain 
types of supplemental testing is unlawful in 
many countries. In the U.S., refer to 
http://www.fda.gov/cber/products/testkits.htm 
for the actual list of U. S. Food and Drug 
Administration (FDA) approved commercial 
diagnostic tests. Commercial tests for diagnostic 
use in Europe need to be Communauté 
Européenne (CE)-marked. 
Only very general descriptions of procedures are 
given in the following sections, since 
commercial test kits all contain detailed step-by-
step instructions. For procedures that are not 
commercially available, the reader is directed to 
the referenced literature. The intent is to guide 
the reader through the multitude of available 
procedures and to discuss their strengths and 
weaknesses. 
 
Screening for HIV Infection, Early Infection 
Window Periods 
HIV-specific antibodies are produced within a 
few weeks after infection. The time to positivity 
in screening tests (i.e., to seroconversion) may 
be influenced by the phenotype of the infecting 
virus, the infectious dose, the transmission 
mode, and the sensitivity of the assay.  
In a study based on the first generation of HIV 
antibody screening assays, developed more than 
two decades ago against subtype B, 
seroconversion was estimated to occur on 
average 45 days after infection; with 95% 
certainty the window period for 90% of 
individuals was less than 20 weeks(Petersen et 
al., 1994). The usefulness of more recently 
developed tests in reducing the average window 
period has since been estimated as follows: 
third-generation anti-HIV-1/2 enzyme 
immunoassays based on detection of antibodies, 
-20.3 days (95% confidence interval [CI], 8.0 to 
32.5); use of p24 antigen or PCR for proviral 
DNA , -26.4 days (CI, 12.6 to 38.7); and PCR 
for viral RNA in plasma, -31.0 days (CI, 16.7 to 
45.3) (Busch et al., 1995). With modern third-
generation antibody-screening assays, half of the 
infected individuals should become antibody 
positive within 3 weeks after infection. Most of 
the other half should become positive within 2 
months, but 5% still seroconvert more than 6 
months after infection. It is important to realize 
that the use of tests for viral RNA, DNA, or p24 
in such patients reduces the long diagnostic 
window periods only insignificantly by 1 to 2 
weeks (Busch et al., 1997).  
Compared to the 3 weeks median window of 3rd 
generation antibody assays, p24 antigen testing 
or the use of 4th generation combination assays 
that detect both HIV antibodies and p24 antigen 
reduces the window by a further 5 days (i.e., to 
16 days). Finally, the most sensitive test 
currently available, a test for HIV-1 RNA with a 
detection limit of 50 copies/ml, reduces the 
median window length by a further 7 days (i.e., 
to 9 days). The viral load at which p24 antigen 
would be detected was estimated by regression 
analysis at 10,000 copies/ml (CI 2,000 to 
93,000) and the HIV replication rate at 0.35 log 
copies/ml/day, corresponding to a virion 
doubling time in the preseroconversion phase of 
20.5 h (Fiebig et al., 2003). Note again that the 9 
day window period for HIV-1 RNA tests is a 
median and that, as mentioned above, the most 
sensitive tests for HIV-1 RNA do not 
significantly shorten the window period of 
patients with late seroconversion. Late 
seroconversion cannot be excluded by a negative 
HIV-1 RNA test. 
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Formats of Screening Tests 
There are numerous commercial HIV tests for 
screening, and it may be difficult to recognize 
the advantages and disadvantages of a particular 
test based on the information given by the 
manufacturer and without systematic 
comparison (Courouce, 1999). An overview of 
different test formats and their properties is 
given in Fig. 6. 
The most important kit formats used for HIV 
antibody screening are the indirect binding 
assay, the antibody capture assay, and the 
double-antigen sandwich (DAGS) assay. 
Indirect binding assays comprise the so-called 
first-generation enzyme-linked immunosorbent 
assays (ELISA), which are based on purified 
viral lysate, and so-called second-generation 
tests which utilize recombinant antigen or 
synthetic peptides usually representing Gag and 
transmembrane (TM) protein. The first-
generation indirect binding assay format also 
applies to immunofluorescence tests and 
Western blot (WB). Line immunoassays (LIA), 
which use recombinant proteins and synthetic 
peptides, may be considered second-generation 
tests. Antibody capture assays usually employ 
recombinant proteins; their principle is that of 
an indirect binding assay reversed. DAGS 
assays, frequently also called third-generation 
assays, usually employ recombinant antigen. 
Particle agglutination assays may be considered 
a variant of DAGS assays because for 
generating a positive signal an antibody 
molecule must react with at least two antigen 
molecules, each located on a separate gel 
particle.  
Although all of these tests detect antibodies, 
they vary in their precise diagnostic questions 
and answers. Indirect binding assays and 
antibody capture assays verify, by binding the 
sample's HIV-specific antibodies to an 
immunoglobulin (Ig)-specific reagent, that the 
component that causes reactivity in such a test is 
indeed an Ig. In contrast, the identity of a 
component causing reactivity in a DAGS assay 
remains uncharacterized; the only information 
provided is that it is capable of linking solid-




FIGURE 6 Kit design and test performance of HIV screening tests. Synopsis of the most frequently used test formats, their 
principles, the meaning of positive results, and performance in two typical problem situations. Ag, antigen; Ab, antibody; Ig, 
immunoglobulin; EIA, enzyme immunoassay; LIA, line immunoassay; WB, Western blot. 
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The different kit formats are affected in 
different ways by diagnostic challenge 
situations. One such challenge is antigenic 
variation. The virus with which a patient is 
infected may exhibit antigens which differ 
considerably from the antigens used in the test. 
Consequently, the patient's antibodies may not 
bind well to the test kit's antigens, and if the 
antibody titer is low, a false-negative result may 
be generated. This type of problem was 
recognized when antibodies induced by HIV-2 
infection were not well recognized by screening 
kits based on HIV-1 antigens alone. This led to 
the inclusion of HIV-2 components, usually of 
the TM protein, in the kits. A similar problem 
was recognized when group O viruses were 
discovered, leading to inclusion of group O 
antigens into all CE marked test kits in Europe 
(De Leys et al., 1990; Gurtler et al., 1994). 
DAGS assays are the assays most affected by 
antigenic variation, because an antibody 
molecule must bind at least two antigen 
molecules in order to generate a signal. Such 
double binding is unlikely if the kit's antigens 
and the patient's antibodies do not fit. Moreover, 
endogenous soluble viral antigen present in the 
serum sample may compete with the test's 
antigens for free binding sites on HIV-specific 
antibodies. IgG, which contains only two 
antigen binding sites per molecule, is most 
strongly affected since a single endogenous 
antigenic molecule suffices to abolish detection 
of an IgG molecule in a DAGS assay. In 
contrast, in indirect binding and antibody 
capture assays, antibodies need bind only a 
single antigen molecule in order to generate a 
signal.  
Another diagnostic challenge is early 
seroconversion. Antibodies in this phase are 
restricted to a few viral antigens (usually 
envelope and p24) and are of low titer and low 
affinity, and the dominating isotypes are IgM 
and possibly IgA. In addition, these antibodies 
may be partially complexed with HIV antigen, 
which is usually present at high concentration in 
primary HIV infection (Fig. 5). In this situation 
it is important that the test provides a high 
concentration of that antigen that is best 
recognized. This goal is more easily achieved 
with recombinant proteins than viral lysate. 
Furthermore, the test must select for the few 
HIV-specific antibodies present in the bulk 
immunoglobulin; this is impossible with 
antibody capture assays that bind Ig of all 
antigenic specificities. In addition, the test 
should detect IgM because, in the presence of 
antigenemia, its pentameric structure with a 
total of 10 antigen binding sites is most likely to 
have several sites remaining accessible. The 
best assay in this situation is the DAGS assay: it 
initially selects for HIV-specific antibodies 
(binding to solid phase), and does not 
discriminate against non-IgG isotypes. The first 
test based on this principle was the particle 
agglutination assay, which was introduced in the 
mid-1980s, i.e., long before third-generation 
ELISA were developed. This test performs 
remarkably well in seroconversion panels, and 
due to the broad spectrum of antigens present in 
the viral lysate it also has a broad detection 
range for antigenic variation (Constantine et al., 
1994; Vercauteren et al., 1995; Poljak et al., 
1997; Lien et al., 2000). 
The practical relevance of these considerations 
is shown when the performances of different 
kits with seroconversion panels are compared. 
Among 23 different commercial kits whose 
performance on at least 15 different 
commercially available seroconversion panels 
was compared by the Swiss Federal Office of 
Public Health, the 17 DAGS assays were the 
most sensitive and occupied ranks 1 to 15, 17, 
and 18. The four indirect binding (2nd 
generation) assays occupied ranks 16, 19, 21, 
and 22, and the two antibody capture assays 
ranked 20th and 23rd (unpublished data of the 
author). Seroconversion panel comparisons also 
demonstrated the inferior sensitivity of 
immunofluorescence tests and WB, which 
ranked at the end together with other first-
generation indirect antibody binding assays (see 
also (Busch and Satten, 1997; Thorstensson et 
al., 1998)). Assessment of the performance in 
seroconversion panels followed by revocation of 
approval for the 1020% least sensitive kits, is 
one of the most powerful — though obviously 
underused — instruments by which regulatory 
agencies could guarantee a continuous further 
technical improvement of diagnostic tests 
(Schupbach, 1996).  
 
Fourth-Generation Screening Tests  
Several companies now offer kits that detect 
both antibodies and antigen (fourth-generation 
tests), and in many European countries the use 
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of these products for HIV screening performed 
in diagnostic laboratories has become 
mandatory. In seroconversion panel analysis, 
these kits now rank first among all screening 
tests even if their detection of antibodies is 
based on the insensitive antibody capture 
format. The average gain in time to detection 
compared with third-generation kits is 3-5 days 
(Gurtler et al., 1998; Weber et al., 1998; 
Laperche et al., 2000; Ly et al., 2001). The use 
of such tests for screening is strongly 
recommended because individuals in the 
antigen-positive stage of pre-seroconversion 
have a high viral load and are particularly 
infectious (Fig. 5). 
 
Rapid Tests and Use of Alternative Specimens 
Rapid tests can be performed with minimal or 
no laboratory equipment; they yield results 
within 30 minutes. Such tests may be useful in 
certain situations, e.g., in assessing the risk of 
HIV transmission in needle-stick injuries and 
similar exposures to possibly HIV-contaminated 
materials, organ donations, or whenever a 
laboratory test result may not be available 
quickly. Rapid tests may be of different formats, 
including DAGS, indirect binding, Ig capture, 
agglutination, or chromatographic assay. The 
diagnostic sensitivity of some of these tests 
seems somewhat inferior to third-generation 
ELISA-based antibody tests, especially in 
seroconversion panels (Kuun et al., 1997; 
Vallari et al., 1998; Giles et al., 1999). Others, 
however, exhibit a comparable diagnostic 
sensitivity and specificity, even during 
seroconversion and can therefore be 
recommended for certain diagnostic settings 
(Giles et al., 1999; Kelen et al., 1999; Palmer et 
al., 1999; Zaw et al., 1999; Phillips et al., 2000; 
Ketema et al., 2001).  
Many persons infected with HIV are not tested 
until they develop symptoms of AIDS. Up to 
one-third of patients receive their HIV diagnosis 
within 2 months of progression to AIDS. The 
hope that such individuals could be motivated to 
be tested earlier has led to new testing 
strategies, particularly in the U.S.. These now 
recommend routine, "opt-out" testing in all 
health-care settings (Branson et al., 2006). The 
shift in testing strategy also has led to the use of 
new test systems believed to be more attractive 
to the client. They include home collection test 
systems, in which sample collection devices are 
ordered by phone and delivered by express 
courier. Blood is collected by finger pricking 
onto filter paper and sent to a designated 
laboratory for screening. Such testing systems 
have good sensitivity and specificity; collecting 
a sufficiently large specimen may be the biggest 
problem, affecting 7-10% of the users. As an 
alternative, testing systems for other specimens, 
such as oral fluids or urine, also received FDA 
approval (reviewed in Mylonakis et al., 2000). 
Excellent sensitivity and specificity were 
reported in studies involving oral fluids 
collected from postseroconversion individuals 
(Saville et al., 1997; Wisnom et al., 1997; 
Granade et al., 1998; Martinez et al., 1999). 
This also applies to FDA-approved test systems 
for urine samples (Urnovitz et al., 1997). Very 
recently, the FDA has approved a rapid test 
system for oral fluids, whole blood or serum, 
which is so easy to perform that testing at the 
point of care with a return of the result within 
20-40 min has become possible. Extended 
studies of this device have reported a sensitivity 
and specificity comparable to that of other EIAs 
(Delaney et al., 2006; Wesolowski et al., 2006). 
The sensitivity of test systems utilizing 
specimens other than blood in early 
seroconversion remains untested, as 
standardized materials comparable to 
seroconversion panels are not available. The use 
of such alternative tests in recent exposure 
settings should therefore be avoided. True home 
tests, which would be sold to the public, have 
not been approved by the FDA or the health 
authorities of other countries, and their safety 
cannot be guaranteed. 
 
Supplemental Testing 
Antibody Tests — Western Blot (WB) and Line 
Immunoassay (LIA) 
WB was introduced into HIV testing by the 
author in 1984 (Sarngadharan et al., 1984; 
Schupbach et al., 1984), proposed for systematic 
confirmation of reactive screening results in 
1985 (Schupbach et al., 1985), and has remained 
a principal confirmatory tool worldwide 
(Mylonakis et al., 2000). Over the years it has, 
however, also become clear that, in contrast to 
the continuously improved screening tests, WB 
has remained a first-generation test with certain 
well-known flaws: the sensitivity in 
seroconversion panels is clearly inferior to that 
of third- and fourth-generation screening tests. 
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WB is also prone to detect cross-reactive 
antibodies, which results in a high rate of 
indeterminate results.  
A single improvement, the use of recombinant 
proteins and synthetic peptides for the 
production of the strips, has been realized by 
some manufacturers. When recombinant 
proteins and peptides are used entirely instead 
of viral lysate, strips can be produced as LIA in 
which selected antigens are applied as distinct 
lines and at defined, optimal concentrations. In 
format, such assays are comparable to 2nd 
generation screening EIAs and may thus be 
considered as "2nd generation Western blots". 
One such assay, the Inno-LiaTM HIV I/II Score, 
is increasingly used in countries outside the 
U.S.. It contains 7 HIV antigen bands (sgp120 
[including group O peptides], gp41, p31, p24 
and p17 of HIV-1; sgp105 and gp36 of HIV-2), 
which are coated as discrete lines on a nylon 
strip with plastic backing. As each test strip also 
contains 3 quantitative internal standards, a 
semiquantitative ranking of the different 
antibody reactions into 6 intensity scores is 
possible. This enables a standardized 
interpretation of test reactions which, unlike for 
WB, is not only based on the presence of 
reactions (yes/no), but also their intensity. This 
LIA provides excellent confirmation of HIV 
infection and is superior to WB for 
differentiating between HIV-1 and HIV-2 
infection (Pollet et al., 1991; Walther et al., 
1995).  
Early identification of HIV-2 infection is 
important with regard to both virus load 
quantification and the choice of effective 
antiretroviral treatment. None of the virus load 
assays approved for patient monitoring can 
reliably quantitate HIV-2, and HIV-2 virus 
loads in symptomatic patients may be severely 
underestimated. Furthermore, HIV-2 is naturally 
resistent to NNRTI and some other antiretroviral 
drugs effective against HIV-1. HIV-2 infection 
must therefore be diagnosed early in order to 
prevent suboptimal disease monitoring and start 
of ineffective treatment regimens leading to 
resistance.  
WB and LIA are more prone to problems with 
carryover contamination than are most 
screening assays. Use of the convenient 
multichannel troughs for incubation of the strips 
presents a certain risk. Contamination with 
minute volumes of a strongly positive serum 
may lead to faint Env bands, even if the dilution 
is up to 106-fold. While intra-assay 
contamination can be ruled out by repeating the 
assay in an isolated test chamber, repeat testing 
will not identify contamination within the 
specimen tube. Touching the wet inner side of a 
specimen tube lid with the gloved fingers may 
carry enough material to the lid of a 
subsequently opened tube to result in faint WB 
reactivity to Env antigens. The probability of 
such events depends on the proportion of 
strongly positive sera among the specimens 
tested by a laboratory and on how many times a 
specimen tube is opened. To minimize this risk, 
handling and testing of samples from known 
HIV-positive patients together with diagnostic 
samples should be avoided, and gloves that have 
become contaminated with specimen must be 
changed immediately. It should also be 
recognized that samples with initial borderline 
results carry an increased risk of contamination, 
since these tubes are opened repeatedly for 
supplemental testing. This results in a higher 
cumulative risk of contamination. Alarm bells 
should ring when a sample with borderline or 
low positive results in screening is faintly 
reactive in WB. It may be an early-
seroconversion sample, but it may also be the 
result of contamination. The contamination 
problem is a strong reason why WB 
interpretation should follow the most stringent 
and not the most sensitive guidelines.  
WB, and to a lesser degree, LIA still have a 
relatively high rate of indeterminate results 
(Pollet et al., 1991). This shows that 
indeterminate WB reactions are usually caused 
by antibodies that cross-react with viral rather 
than with cellular proteins. Indeterminate WB 
results have been described for patients with 
autoimmune disorders, in particular systemic 
lupus erythematosus, after infections with 
certain viruses including herpes simplex virus 
type 1 or cytomegalovirus, or after vaccination 
against influenza or rabies virus (Guan, 2007). 
For the latter, epitopes related to HIV have been 
implicated. Such information is, however, of 
little practical value, and the origin of 
indeterminate WB reactions usually remains 
obscure. In spite of all these flaws, a WB or LIA 
with a "full-house" pattern of reactive antibodies 
probably remains the most convincing 
laboratory evidence for an HIV infection. When 
reactive bands are few and their intensities are 
low, interpretation is hazardous, and a diagnosis 
must not be based on WB or LIA alone.  
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WB Interpretation Guidelines 
In an attempt to render WB more sensitive, the 
Association of State and Territorial Public 
Health Laboratory Directors and the CDC 
(ASTPHLD-CDC) issued interpretation 
recommendations which request antibody 
reaction to any two of three antigen bands 
including gp120/160 (considered to be one 
antigen), gp41, and p24 (Anonymous, 1989). 
Since most of the gp160 and gp120 bands on 
WB are not due to the Env precursor or the 
surface (SU) protein but instead represent 
tetramers or trimers of gp41 (Pinter et al., 1989), 
reaction with gp120-gp160 and gp41 bands may 
be based on reaction with a single protein, TM, 
and is thus inherently unsafe. The same is true 
for the very similar recommendations by the 
Consortium for Retrovirus Serology 
Standardization, the only difference being that 
p24 may be replaced by p31(pol). Similarly, the 
World Health Organization recommendation 
specifies any two of gp160, gp120, and gp41 
(Anonymous, 1990). This means practically that 
TM-reactive antibodies must be present at a 
concentration sufficient for detection of not only 
the strongest but also the second-strongest TM 
band. The strongest TM band is usually the 
largest antigen, i.e., gp160, which migrates least 
far in the sodium dodecyl sulfate-
polyacrylamide gel electrophoresis–based 
separation of proteins and thus is the sharpest 
and best-detected band. Depending on the 
manufacturer, either gp120 or gp41 may be the 
second strongest band. Due to varying degrees 
of glycosylation, gp41 migrates in sodium 
dodecyl sulfate-polyacrylamide gel 
electrophoresis as a very diffuse band. Reactive 
antibodies thus generate a signal that is much 
less easily recognized than if the same 
antibodies bind to the sharp gp160 band. 
Due to the propensity of WB to detect cross-
reactive antibodies, a combination of Env and 
p24 bands is not sufficiently stringent for 
confirmation. WB analysis of 100 screening-
negative but otherwise unselected Swiss blood 
donors showed an isolated reaction with p24 in 
9% and with gp160 or both gp160 and gp120 in 
3%. The likelihood of a chance combination 
leading to "confirmed positivity" in a healthy 
donor would thus be 0.09 x 0.03, or 0.0027, i.e., 
1 in 370 (Schupbach et al., 1990). We and 
others (Healey and Bolton, 1993) have observed 
several cases that satisfied the ASTPHLD-CDC 
criteria for WB positivity and kept this pattern 
essentially unchanged over years but were 
negative in long-term follow-up in all direct 
tests for HIV components, including virus 
culture, regular polymerase chain reaction 
(PCR) for HIV DNA and RNA, and an 
ultrasensitive sequence capture-PCR test 
"Mega-PCR" enabling detection of a few 
provirus copies in as much as 100-500 µg of 
DNA (Boni et al., 2004b). Representative WB 
results of such a case are shown in Fig. 7.  
More-stringent criteria have been issued by the 
American Red Cross (ARC) and the FDA. ARC 
specifies at least one band each from Env, Gag, 
and Pol. The most stringent, but least sensitive 
recommendation is that of the FDA, which 
specifies reaction with p24, p31, and Env.  
 
FIGURE 7 Example of a false-positive HIV-1 WB 
interpretation according to ASTPHLD-CDC or CRSS 
guidelines. Lanes: a, weakly positive control; b, sample 
from a healthy individual exhibiting weak reaction with 
gp160, gp120 (very weak), and p24 (this sample was taken 
3.5 m after an initial sample with the same pattern [data not 
shown]); c, sample from the same individual taken 1 month 
after the initial sample. p24 antigen with signal 
amplification–boosted ELISA was negative in all three 
plasma samples; PCR for viral DNA was negative in 
PBMC from the samples in lanes b and c, and RNA was 
negative in the sample in lane b. Culture with PBMC 
depleted of CD8 T cells from the sample in lane b was 
negative for p24 antigen and RT by the PERT assay; this 
test was also negative with the samples in lanes b and c.  
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In my opinion, only the most stringent 
interpretation guidelines should be applied if a 
diagnosis of HIV infection is established using 
WB as the only supplemental test. If some true 
cases of HIV infection are WB indeterminate by 
FDA guidelines, this is of no concern as long as 
their WB pattern is suggestive of HIV infection. 
This is always the case when the ASTPHLD-
CDC interpretation would render these patterns 
positive. In almost all such cases, a safe 
diagnosis can be established based on 
supplemental tests for virus components (p24 
antigen or nucleic acids). One also has to take 
into account that the ASTPHLD-CDC criteria 
were established based on a single commercial 
product. Meanwhile, other kits are available. 
Guidelines established for one particular kit and 
with one particular sample cohort cannot be 
applied to other kits or populations from other 
geographical regions without careful re-
examination of their validity. 
Another attempt to render WB more sensitive in 
early infection is its use in the detection of IgM. 
Unfortunately, such testing lacks specificity. 
Gag-reactive antibodies of IgM, IgA, and IgG 
isotype are frequently detected by WB in sera of 
infants born to HIV-negative mothers. 
Therefore, many of these reactions appear to be 
due to common agents unrelated to HIV 
(Schupbach et al., 1994). 
 
Virus Component Tests — p24 Antigen and 
Nucleic Acid Tests (NAT) 
In many cases, supplemental testing requires the 
use of tests for virus components. This applies 
to patients in primary HIV infection as well as 
those with indeterminate results in antibody 
tests. Diagnosis of pediatric HIV infection is 
also best established with virus component tests. 
Virus components that can be assayed include 
the p24 antigen, viral DNA or RNA, and RT 
activity. In addition, the capability of the virus 
to replicate can be assessed by virus isolation in 
cell culture. This requires a virus component 
test, usually an antigen test or 
immunofluorescence for cell-associated HIV 
antigen. 
Commercially available tests for virus 
components include p24 antigen assays. CE-
marked p24 antigen assays are available from 
various manufacturers in Europe, while in the 
U.S. only one test is FDA-approved. A CE-
marked kit is available for PCR detection of 
HIV-1 DNA, but lacks approval in the U.S. 
NAT for HIV-1 RNA that are both CE-marked 
and FDA-approved are available from several 
manufacturers and currently include PCR for 
reverse-transcribed RNA (RT-PCR), nucleic 
acid sequence-based amplification (NASBA) 
which is also known as transcription-mediated 
amplification (TMA), and a signal-amplification 
procedure which involves branched DNA 
(bDNA) probes.  
 
Tests for HIV p24 Antigen 
Antigen tests for p24 are easy to perform and 
diagnostically valuable in early infection, when 
antigen is usually present at high titers while 
HIV-specific antibodies may still be 
undetectable. Although NAT are increasingly 
used instead of p24 antigen, this test still has a 
place in supplemental testing because it can, in 
contrast to NAT, also be performed on serum, 
thus enabling diagnosis of primary infection in 
the first specimen received for HIV testing, 
usually serum. A highly improved version of a 
p24 antigen test, involving a signal 
amplification boosted p24 EIA of heat-
denatured plasma also has proven to be a 
sensitive, specific, simple and inexpensive 
solution for diagnosing pediatric HIV-1 
infection in resource-poor settings, especially in 
subtype C epidemics (Schupbach, 2003; Fiscus 
et al., 2006; Patton et al., 2006).  
 
Tests for Viral RNA or DNA  
Three fundamentally different techniques for the 
sensitive detection or quantification of HIV 
RNA or DNA are available.  
Polymerase Chain Reaction (PCR) In PCR, 
double-stranded DNA is denatured, a pair of 
HIV-specific oligonucleotide primers is 
annealed to the separated viral DNA strands, 
and these primers are extended by a heat-
resistent DNA-dependent DNA polymerase 
(Taq polymerase). This procedure is continued 
for 30 to 40 cycles, each of which comprises a 
high-temperature denaturation, a low-
temperature primer annealing, and an 
intermediate-temperature primer extension 
(DNA synthesis) (Kwok et al., 1987). If the 
starting material for PCR is RNA, a cDNA must 
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first be generated by reverse transcription. This 
cDNA can then be amplified by the regular 
procedure (Byrne et al., 1988). A further 
development of PCR, TaqMan® real-time PCR, 
employs the AmpliTaq Gold® DNA polymerase 
for PCR amplification. This enzyme also has a 
5′ exonuclease activity, enabling it to cleave 
away a synthetic oligonucleotide called a 
TaqMan® probe annealed to a specific sequence 
of the template between the forward and reverse 
amplification primers. The probe, which 
contains a fluorophor at the 5'-end and a 
quencher at the 3'-end, sits in the path of the 
enzyme as it proceeds to copy DNA or cDNA. 
When the enzyme reaches the annealed probe it 
cleaves the probe into its nucleotides, thus 
releasing the fluorophor from the inhibitory 
effect of the quencher. Thus, the growing copy 
number of amplified DNA is accompanied by a 
likewise increasing intensity of fluorescence, 
which is measured continuously, thus permitting 
real-time observation of the amplification 
process. Important advantages of real-time PCR 
include the broad range of concentration in 
which the target DNA is measured precisely and 
the protection against carry-over contamination, 
as both amplification and product analysis take 
place in a closed system.  
RT-PCR test systems for both manual sample 
preparation and or fully automated operation are 
available from both Roche (Roche Molecular 
Diagnostics, Pleasanton, California) and Abbott, 
(Abbott Laboratories, Abbott Park, Illinois). The 
assays manufactured by Roche (Amplicor HIV-
1 Monitor Vs. 1.5, Cobas AmpliPrep/Cobas 
TaqMan HIV-1) amplify a sequence in gag, 
which permits good detection of the various 
subtypes of HIV-1 group M and most CRFs, but 
not of group O or HIV-2 (Triques et al., 1999; 
Katsoulidou et al., 2006; Schumacher et al., 
2007). Abbott's tests (LCx HIV RNA 
Quantitative, RealTime HIV-1 assay for use on 
the m2000 system) amplify a conserved 
sequence in the integrase region of pol and 
detect groups N and O in addition to the various 
subtypes and CRFs of group M (Swanson et al., 
2005; Swanson et al., 2006; Swanson et al., 
2007). Although the intended primary purpose 
of these tests is for patient monitoring (virus 
load determination), they are used also 
diagnostically, in particular for diagnosing acute 
HIV-1 infection.  
 
Nucleic Acid Sequence Based Amplification 
(NASBA) and Transcription-Mediated 
Amplification (TMA) In the NASBA and TMA 
procedures RNA is amplified in an isothermal 
multienzymatic procedure mediated by the 
enzymatic effects of RNA-dependent DNA 
polymerase (RT), RNase H, DNA-dependent 
DNA polymerase, and DNA-dependent RNA 
polymerase. This procedure thus mimics the 
retroviral nucleic acid replication cycle (Fig. 1). 
The product of this amplification is a single-
stranded RNA (Kievits et al., 1991). In current 
NASBA and TMA kits, the resulting RNA 
product is detected by a specific DNA probe 
(molecular beacon) which, when annealed to the 
target RNA, forms a stem-loop structure 
resulting in emission of a chemoluminescent 
signal. 
Currently available kits include a CE-marked 
and FDA-approved quantitative real-time 
NASBA kit (NucliSENS EasyQ) from 
bioMerieux, Marcy l'Etoile, France, which 
amplifies a sequence in the gag gene, and a 
TMA-based HIV-1 RNA qualitative assay 
(APTIMA HIV-1 RNA Qualitative Assay) 
manufactured by Gen-Probe, San Diego, CA. 
The latter is an FDA-approved assay for 
diagnosis of HIV-1 infection in human plasma. 
The assay amplifies conserved sequences in 
both the LTR and pol of HIV-1 thus enabling 
simultaneous detection of all known groups of 
HIV-1, i.e., M, N and O. It is intended for use in 
the diagnosis of HIV-1 infection, including 
acute or primary infection (Roland et al., 2004). 
The same test principle and target sequences 
also are used in an FDA-approved test for fully 
automated blood donor screening with 
simultaneous detection of HIV-1, hepatitis B 
virus and hepatitus C virus RNA (Linnen et al., 
2002; Candotti et al., 2003; Koppelman et al., 
2005). 
Branched DNA (bDNA) In the bDNA method 
viral RNA is captured on a solid surface by 
immobilized specific capture probes. The 
captured RNA is then reacted with "connector" 
probes, which with one end hybridize to a series 
of short sequences of the pol region of the RNA 
and with the other end mediate fixation of 
bDNA detector probes. These bDNAs are then 
reacted with still other bDNAs that hybridize to 
the first. Enzyme-labeled tracer probes are 
finally hybridized to all the branches, and the 
analysis is based on chemoluminescence (Urdea 
et al., 1993). The principal difference of the 
bDNA method compared with PCR or NASBA-
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TMA is the lack of amplification of viral 
sequences and, in consequence, lack of a 
carryover problem. What is called signal 
amplification is in fact a mere signal 
accumulation in which interacting molecular 
probes added to the reaction mixture at 
predetermined high concentration are hybridized 
to captured viral RNA in an ordered process 
which results in the deposition of consecutive 
probe layers. The procedure is in fact 
comparable to an indirect antibody-binding 
assay. Higher precision is probably achieved 
than with nucleic acid amplification techniques, 
whose outcome depends on the efficacy of 
primer annealing in each cycle.  
A bDNA-based assay for HIV-1, the Versant® 
HIV-1 RNA 3.0 (bDNA), is sold by Bayer 
HealthCare, Leverkusen, Germany (Galli et al., 
2005). This test is based on about 40 different 
probes that cover most of the pol gene and 
permit detection of the various subtypes of 
group M but not of group O. A drawback of the 
method is the relatively high detection limit, 
which must be compensated by large specimen 
volumes (2 ml of plasma).  
Nucleic acid tests with FDA approval and their 
intended uses are listed on 
http://www.fda.gov/cber/products/testkits.htm. 
With the exception of TMA and the RT-PCR 
based systems for blood donor screening, the 
kits described above are designated primarily 
for quantification of viral RNA. Depending on 
specificity and level of detection, some of them 
under certain conditions also may be suitable for 
diagnostic (qualitative) purposes, but caution 
must be exercised since false positive results 
have been reported (Roland et al., 2004). Of 
note, the cut-off for the Bayer Versant HIV-1 
RNA 3.0 (bDNA) has been set in a way that will 
result in 5% false-positives when used on 
uninfected controls! For diagnostic questions, it 
is therefore safer to use qualitative tests such as 
the APTIMA HIV-1 RNA Qualitative Assay 
(Gen-Probe). There is one CE-marked 
commercial PCR kit for HIV-1 DNA (Roche), 
but there are reports of false-negative results 
with this kit, particularly with non-B subtypes 
(Bogh et al., 2001; Obaro et al., 2005). Many 
diagnostic laboratories, including ours, have 
developed their own PCR methods for 
qualitative detection of viral DNA or RNA. 
Detailed step-by-step instructions for our 
diagnostic procedures, which are capable of 
detecting a single DNA copy even without using 
nested-PCR protocols (which carries a high risk 
of carry-over contamination), were published 
(Boni, 1996). For quantification of viral RNA a 
number of excellent real-time RT-PCR systems 
have been described (Drosten et al., 2006; 
Muller et al., 2007; Rouet et al., 2007).  
The availability of commercial kits for the 
detection of HIV-1 RNA or DNA by sequence 
or signal amplification has rendered these tests 
attractive for laboratories with no background in 
molecular biology. The fact that under optimal 
circumstances a single gene copy can be 
detected by some of these tests has created a 
relatively uncritical attitude, resulting in a 
degree of trust that is not justified in several 
aspects. Molecular tests are sensitive to 
sequence variation, resulting in underdetection 
or false-negative results in some cases. 
Carryover contamination, whose main source is 
amplified DNA but which may also originate 
from other specimens, can also be a problem, 
and commercial products or systems must 
therefore have built-in carryover protection 
devices. In addition, precautionary measures are 
vital for all laboratories performing such tests 
(Boni, 1996).  
Important factors in molecular testing are 
sample handling and sample preparation. 
Particle-associated RNA in plasma has been 
claimed to be very unstable, demanding special 
expensive plasma preparation tubes from a 
certain manufacturer and immediate separation 
of plasma from the cellular pellet before the 
sample is shipped to the laboratory. Independent 
investigators have not been able to confirm 
these claims. Their work indicates that HIV-1 
RNA levels are stable (variance, less than 0.3 
log unit) for up to 3 days after collection when 
stored either at room temperature or at 4°C as 
cell-free plasma in the ethylenediamine 
tetraacetic acid (EDTA)-plasma preparation 
tubes or even as EDTA-anticoagulated whole 
blood in regular tubes. Comparison of paired 
HIV-1-positive plasma and serum specimens 
revealed that RNA quantitation was 20-65% 
lower in serum than in plasma. EDTA plasma is 
thus the preferred specimen for these assays and 
provides the highest levels of RNA. EDTA 
plasma that is prepared and frozen within 8 h of 
collection can thus be trusted to be of sufficient 
quality for these tests. It can be thawed and 
frozen up to three times before the RNA levels 
decrease significantly (Todd et al., 1995; 
Ginocchio et al., 1997; Sebire et al., 1998). 
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The maximal sensitivity of molecular tests is 
limited by sample size and sequence variation. 
The detection limit of the PCR is a single DNA 
molecule. However, 1 µg of genomic DNA, 
which contains the DNA of approximately 
150,000 cells, corresponds to the number of 
peripheral blood mononuclear cells (PBMC) 
contained in only about 75 µl of blood. 
Consequently, even with a detection limit of one 
provirus/µg of DNA, roughly 70,000 infected 
cells must be present in 5,000 ml of blood for 
PCR analysis to be positive. A detection limit of 
10 copies per reaction is more realistic because 
of the Poisson distribution, which means, for 
example, that not every sample with a nominal 
concentration of one copy/sample indeed 
contains such a copy. Similarly, the sensitivity 
for the detection of particle-associated HIV 
RNA is limited by the efficiency of the reverse 
transcription step and by the volume of analyzed 
plasma. To achieve higher sensitivity 
("ultrasensitive tests"), sample input has to be 
increased to milliliter plasma volumes 
(Schockmel et al., 1997). Loss of sensitivity 
may also be due to HIV sequence divergence. 
Individual mutations at a critical downstream 
position of an amplification primer may lead to 
reduced or entirely abolished amplification. 
Infallible tests based on sequence amplification 
are thus an illusion, but significant progress 
resulting in broader sensitivity has definitely 
been achieved. Subtypes A, CRF02_AE, F, and 
G were systematically underdetected by version 
1.0 of the Roche Amplicor HIV-1 Monitor test 
(Coste et al., 1996; Simons et al., 1997; Debyser 
et al., 1998; Parekh et al., 1999). The 
introduction of modified primers in the 
subsequent version 1.5 of the test considerably 
improved the recognition of these clades, while 
group O isolates remain undetectable. Change 
from Monitor Version 1.5 to Roche TaqMan 
based RT-PCR kits may also result in 
significantly lower copy numbers of HIV-1 
RNA in some instances. 
HIV-1 subtypes A and G were insufficiently 
detected by earlier NASBA kits. Designation of 
new primers for the current real-time version of 
the test, NucliSens EasyQ (bioMerieux) have, 
however, resulted in performance similar to 
Roche's RT-PCR (Lam et al., 2007; Stevens et 
al., 2007). Underdetection of a significant 
fraction of subtype C samples was reported in 
one study from Israel (Gottesman et al., 2006), 
but was not seen in studies performed in South 
Africa (Stevens et al., 2005; Stevens et al., 
2007). On the other hand, the NucliSens EasyQ, 
as the first test so far, has recently been shown 
to enable quantification of subtype A of HIV-2 
(Rodes et al., 2007). Improved recognition of 
group O has been achieved with Abbott's RT-
PCR based tests and the Gen-Probe TMA 
assays. 
Broad application of NAT in the diagnostic 
laboratory has now become feasible as full 
automation of both nucleic acid extraction and 
test conduction has been achieved. PCR is very 
helpful when serology has failed to provide a 
clear answer. This applies in particular to 
specimens with borderline reactivity in 
screening assays or incomplete patterns on 
confirmatory WB or LIA, specimens from 
individuals with suspected primary HIV 
infection (although a p24 antigen test would 
suffice in most instances), and babies of HIV 
infected mothers. For individuals with 
confirmed-positive HIV-1 serology, 
quantification of the viral RNA in plasma is 
essential for clinical assessment and, if positive, 
serves as a further confirmation of the infection. 
 
Virus Isolation  
Leukocytes are separated from anticoagulated 
blood by Ficoll centrifugation and cocultured 
with phytohemagglutinin-stimulated leukocytes 
from healthy blood donors. Culture supernatants 
are periodically assayed for p24 antigen. 
Cultures usually become positive within 2 
weeks, but culture times of up to 60 days have 
been reported (Ho et al., 1989; Burgard et al., 
1992). The procedure has a sensitivity of about 
90% over all stages; the success rate is lower for 
asymptomatic patients. Significant improvement 
may be achieved by complicated procedures 
combining concentration of cells likely to be 
infected; removal of cells that might interfere 
with virus replication, such as CD8 T-cells; and 
activation of infected lymphocytes using 
phytohemagglutinin or antibody to CD3 and 
CD28. Such procedures enabled virus isolation 
from lymph node cells of all patients whose 
viral RNA level in plasma had become 
undetectable under antiretroviral treatment 
(Finzi et al., 1997; Wong et al., 1997). Despite 
these improvements in sensitivity, virus 
isolation remains time-consuming and costly. 
Since PCR for viral DNA or RNA, as well as 
the signal amplification-boosted p24 antigen 
test, have a diagnostic sensitivity of more than 
96% and yields results within 1 day, virus 
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isolation has become unsuitable for the routine 
diagnosis of adult and pediatric HIV infection in 
both developed and resource-poor settings, 
although it remains important for many research 
questions. 
 
Reverse Transcriptase Assays 
Particle-associated RT is a unique marker of 
retroviruses, and RT assays have been 
instrumental in the discovery of all known 
human retroviruses. Tests have now been 
developed that combine the broad detection 
range of RT tests with the high sensitivity of 
nucleic acid amplification procedures. These so-
called product-enhanced reverse transcriptase 
(PERT) assays are based on the selective 
enhancement, by PCR or another amplification 
method, of the cDNA product synthesized from 
an RNA template by the RT activity contained 
in a test sample. They are 106 to 107 times more 
sensitive than a conventional RT test and detect 
fewer than 10 particles (Pyra et al., 1994), thus 
rivaling PCR for detecting viral RNA in plasma 
(Boni et al., 1996a; Reisler et al., 2001). 
Detailed step-by-step instructions have been 
published (Boni and Schupbach, 1999). Assays 
based on this principle were established also by 
others (Silver et al., 1993; Heneine et al., 1995). 
In the context of HIV infection, the PERT assay 
may be diagnostically useful when a low CD4+ 
lymphocyte count or indeterminate serological 
results, such as a WB test result positive 
according to ASTPHLD-CDC but indeterminate 
by FDA guidelines, suggest the presence of an 
HIV infection, possibly with an agent not well 
detected by the current HIV-specific 
amplification methods. A negative result with 
the PERT assay, which would detect any 
retrovirus independent of its genomic sequence, 
excludes infection with an abberrant HIV strain. 
Since a commercial kit is not available, the test 
is currently restricted to specialized retrovirus 
laboratories that also do research. A less 
sensitive test kit lacking amplification has been 
evaluated as an alternative virus load test for 
resource-poor settings (Seyoum et al., 2006). 
Unlike the PERT assay, due to the lack of 




Diagnosis of HIV-2 Infection 
Screening tests, at least in Europe, must 
demonstrate good sensitivity to HIV-2 in order 
to receive CE marking. Detection of HIV-2 
infection at the level of screening is therefore 
not a problem. In contrast, determination of 
whether reactivity in screening is due to 
infection with HIV-1, HIV-2, or both is 
sometimes difficult. On HIV-1 WB, sera from 
HIV-2 infected individuals frequently have 
strong reactions with Gag and Pol proteins 
compared to their reaction with Env. In 
particular, they may present with an unusually 
strong p31 (integrase) band. A suspected HIV-2 
infection is further supported by reaction with 
the recombinant HIV-2 TM protein present on 
the products of some manufacturers. We have, 
however, occasionally seen samples that did not 
react with this band, although HIV-2 infection 
was subsequently confirmed. The presence of 
isolated Gag bands on HIV-1 WB or of strong 
reactivity against p24 and Gag precursors (p55, 
p43, and p39) is not an indication of HIV-2 
infection. Similarly, the presence of faint Gag-
reactive bands on HIV-1 blots is not an 
indication for an HIV-2 WB.  
Results of HIV-1 WB suggestive of HIV-2 
infection may be confirmed by an HIV-2 WB 
or, preferable, by tests involving specific 
recombinant proteins, e.g., an LIA or a rapid test 
that differentiates between the two. If reactions 
to both HIV-1 and HIV-2 proteins are present at 
similar intensities, diagnostic PCR for proviral 
DNA of both viruses is necessary. HIV-2 
infected asymptomatic individuals, i.e., the 
overwhelming majority, have much lower viral 
loads than those infected with HIV-1; HIV-2 
RNA is usually undetectable in these patients. 
The confirmatory test of choice thus is PCR for 
HIV-2 DNA. 
 
Diagnostic Algorithms and General 
Considerations 
Guidelines for HIV testing may vary in different 
countries based on prevalence of virus types, 
available tests, laboratory facilities, health care 
systems, and economic or other factors. Revised 
U.S. recommendations for HIV testing of adults, 
adolescents, and pregnant women in health-care 
settings were issued in 2006 (Branson et al., 
2006); these recommendations are also 
accessible online under 
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(http://www.hivatis.org/Guidelines). FDA-




Initial screening is done with an FDA-approved 
enzyme immunoassay (EIA) for HIV antibodies. 
Specimens with a nonreactive result are 
considered HIV negative unless new exposure 
has occurred. Specimens with a reactive EIA 
result are retested in duplicate. If the result of 
either duplicate is reactive, the specimen is 
reported as repeatedly reactive and undergoes 
confirmatory testing with a supplemental test 
(e.g., WB or immunofluorescence assay). 
Specimens repeatedly reactive by EIA and 
positive by WB or immunofluorescence assay 
are considered HIV positive (Fig. 8, dark area).  
Specimens that are repeatedly EIA reactive 
occasionally provide an indeterminate WB 
result, which might represent either an 
incomplete antibody response to HIV in 
specimens from infected persons or nonspecific 
reactions in specimens from uninfected persons. 
Immunofluorescent antibody (IFA) can be used 
to resolve an indeterminate WB sample. 
Generally, a second specimen should be 
collected >1 month later and retested for 
persons with indeterminate WB results. Nucleic 
acid testing for viral RNA or proviral DNA 
could also help resolve an initial indeterminate 
WB in certain situations. 
An HIV test should be considered positive only 
after screening and confirmatory tests are 
reactive. A confirmed positive test result 
indicates that a person has been infected with 
HIV. False-positive results when both screening 
and confirmatory tests are reactive are rare. 
However, the possibility of a mislabeled sample 
or laboratory error must be considered, 
especially for a person with no identifiable risk 
for HIV infection.  
Because a negative test result probably indicates 
absence of HIV infection, a negative test need 
not be repeated in persons with no new exposure 
in settings with low HIV prevalence. For 
persons with a recent history of known or 
possible exposure to HIV who are tested before 
they could develop detectable antibodies, the 
possibility of HIV infection cannot be excluded 
without follow-up testing. A false-negative 
result also should be considered in persons with 
a negative HIV-1 test who have clinical 
symptoms suggesting HIV-1 infection or AIDS. 
Additional testing for HIV-2 and HIV-1 group 
O infection might be appropriate for these 
persons.  
Most people with an initial indeterminate WB 
result who are infected with HIV-1 will develop 
detectable HIV antibody within 1 month. Thus, 
persons with an initial indeterminate WB result 
should be retested for HIV-1 infection >1 month 
later. Individuals with continued indeterminate 
WB results after 1 month are unlikely to be HIV 
infected and should be counseled as though they 
are not infected unless recent HIV exposure is 
suspected. Nucleic acid tests for HIV DNA or 
RNA are not generally recommended for 
resolving indeterminate WB results except in 
suspected cases of primary or acute infection 
(Divine et al., 2001). 
 
Alternative Testing Strategies  
In contrast to the U.S., where screening does not 
normally include testing for HIV-2 or group O 
viruses, CE-marked screening tests used in 
Europe must detect all HIVs. Great importance 
is placed also on the detection of primary HIV 
infection; therefore, fourth-generation screening 
tests or additional antigen testing are 
recommended whenever a primary HIV 
infection must be considered. Finally, 
verification of all confirmed HIV-positive 
results with a second, freshly drawn specimen is 
mandatory when a diagnosis of HIV infection is 
first established. The peripheral, lightly shaded 
areas of Fig. 8 illustrate possible modifications 
of the U.S. recommendations that may under 
certain circumstances be useful.  
To avoid the practical and financial problems 
associated with WB testing, the WHO has 
recommended alternative test strategies based on 
the use of at least two different screening tests 
(Sato et al., 1994). Large studies have shown 
that such testing algorithms may yield results 
that are at least equivalent to the conventional 
testing algorithm outlined above. In one 
alternative algorithm, reactive samples are 
subjected to a different screening assay and only 
those samples with discrepant results are 
subjected to WB testing. Initial screening may 
also be performed with two different tests, and 
those with discrepancies undergo supplemental 
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testing. Supplemental testing by WB can also be 
replaced without loss in sensitivity or specificity 
by a third screening assay (Laleman et al., 1991; 
van der Groen et al., 1991; Urassa et al., 1992; 
Nkengasong et al., 1999). Given the further 
improvement of screening tests since the time 
most of these studies were done, such testing 
algorithms have become even more attractive. In 
particular, initial screening with a fourth-
generation antibody/antigen test and a third-
generation DAGS test in parallel is bound to 
increase the sensitivity. Samples nonreactive in 
both assays are reported as HIV negative. 
Samples reactive in both assays are almost 
always infected, since the high diagnostic 
specificity (>99.5%) of each of the two tests is 
potentiated, resulting in an overall diagnostic 
specificity of ≥99.9975%. Therefore, a freshly 
drawn confirmatory sample can be directly used 
for quantification of the viral RNA load. An 
HIV-1 RNA concentration above about 5,000 
copies/ml plasma is sufficient additional proof 
of an infection, but is not specific for HIV-1. As 
some HIV-2 isolates are recognized relatively 
well by current RT-PCR test kits while others 
are severely underdetected or recognized not at 
all, there is always the possibility that a patient 
with low to medium level of detectable RNA in 
an HIV-1 test is actually infected with HIV-
2(Schutten et al., 2004). Serological tests able to 
distinguish between HIV-1 and HIV-2 are thus 
the best solution to diagnose, or exclude, HIV-2 
infection. 
Result discrepancy between the two screening 
tests or borderline results may be due to acute 
HIV infection or a nonspecific reaction. Acute 
infection must be suspected if reactivity is 
restricted to the fourth-generation assay; a 
reactive antigen test confirmed by a positive 
antigen neutralization test further supports this 
possibility. If the antigen test result is negative, 
seroconversion is unlikely, and false reactivity 
must be suspected. Since inconsistent or 
indeterminate results may be due to laboratory 
errors (sample mix-up, carryover 
contamination), diagnostic clarity is sometimes 
best achieved with a freshly drawn sample. An 
EDTA-anticoagulated blood sample of at least 7 
ml should be requested. This will permit 
performance of any of the supplemental tests. 
Since nucleic acid tests almost always become 
positive prior to seroconversion, there is no 
rationale for a prolonged interval to clarify 
indeterminate antibody test results. If PCR for 
viral RNA or DNA is negative in such samples, 
an HIV infection as the reason for the 
indeterminate antibody result can be excluded 
for practical purposes.  
Assays performed on the second specimen are 
chosen according to the results of the first 
sample. A confirmatory laboratory should be 
capable of performing a variety of supplemental 
tests to establish a "confirmed diagnosis of HIV 
infection". A third positive screening assay, a 
positive WB according to FDA guidelines, a 
positive and neutralized antigen assay, or PCR 
for viral RNA or DNA may be used alone or in 
combination to establish such a diagnosis, with 
the results obtained with the first sample also 
being taken into consideration (case 
interpretation). Tests performed with the second 
sample should also establish the type of virus 
(HIV-1 or HIV-2), and the viral RNA load and 
may, if indicated, even include antiretroviral 
resistance testing.  
It is important that the diagnosis of an HIV 
infection is never established on a single 
specimen. The possibility that an error might 
lead to a false-positive diagnosis dictates 
verification of all reactive results with a second, 
freshly drawn sample. Also, indeterminate 
results of different methods never add up to a 
positive result. For example, a borderline 
screening test plus a borderline WB with a 
pattern ruled positive according to guidelines 
issued by the Association of State and Public 
Health Laboratory Directors and the Centers for 
Disease Control and Prevention (ASTPHLD-
CDC), but indeterminate by American Red 
Cross (ARC) or FDA criteria, plus a reactive 
antigen test which, however, cannot be 
confirmed by neutralization are not sufficient 
for a confirmed positive diagnosis. Testing must 
continue until clear-cut positive results are 
obtained.  
 
Diagnosis of Pediatric HIV-1 Infection 
Diagnosis of HIV infection in babies born to 
HIV-positive mothers is complicated by the 
presence of HIV-specific IgG antibodies of 
maternal origin; HIV-IgG concentrations in 
term-born babies are as high as in their mothers. 
Since the half-life of IgG is about 3 weeks, 
HIV-specific maternal antibodies disappear 
slowly and may remain detectable for up to 15-
18 months. Early diagnosis of HIV infection in 
maternally exposed infants is thus only possible 
with tests for virus components. PCR for 
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proviral DNA in blood cells or HIV-1 RNA in 
plasma have become the methods of choice 
(Nielsen and Bryson, 2000). Approximately 
one-third of maternally transmitted infections, 
probably those representing transmission in 
utero, can be detected within the first 10 days of 
life. In a few cases, PCR for DNA from PBMC 
may still be negative when PCR for viral RNA 
in plasma is already positive (Steketee et al., 
1997; Cunningham et al., 1999; Young et al., 
2000). The remainder, assumed to have become 
infected at birth, become PCR positive within 
the next 2 months. Several studies have shown 
that testing of heat-denatured plasma samples by 
signal amplification–boosted p24 antigen EIA 
diagnoses pediatric HIV-1 infection with 
sensitivity and specificity similar to that of tests 
for viral DNA or RNA (Nadal et al., 1999; 
Fiscus et al., 2006). Tests for HIV-1 DNA, 
RNA, or p24 antigen can also be conducted on 
dried blood spots specimens (Patton et al., 2006; 




FIGURE 8 Algorithms for diagnosis of HIV infection in adults. The darker shading represents algorithms of U.S. guidelines; the 
lighter shading illustrates possible alternatives. Reprinted from the Manual of Clinical Microbiology, 8th Edition (Schüpbach, 
2003) with permission of the publisher. 
 
HIV Disease and Treatment Monitoring 
Determination of the HIV RNA concentration 
(viral load) is instrumental in several aspects for 
the clinical management of HIV infection (for 
updated online comprehensive treatment 
information and guidelines refer to 
http://aidsinfo.nih.gov/ or 
http://www.hivatis.org/?list/). First, in early 
infection at the set point it serves to assess the 
likely course the infection will take. In untreated 
patients, the viral load and CD4+ T-cell count 
are measured every 3-4 months. Treatment 
decisions are taken based on the CD4+ T-cell 
count and the viral load. When patients start 
antiretroviral treatment (ART) or after change in 
ART, drug efficacy is initially assessed by 
measuring the viral load after 2-8 weeks. The 
next viral load measurement for assessment of 
antiviral effect is performed 3-4 months after 
start of ART, and at 3 to 4 months intervals 
thereafter. Outside of such regular 
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measurements, the viral load is also determined 
in case of clinical events or a significant decline 
in CD4+ T-cells (Anonymous, 2006).  
 
Prognostic Value of Viral Load 
Higher HIV RNA levels correlate with lower 
baseline CD4+ T-cell counts, a more rapid 
decline in CD4+ T-cell counts, and more rapid 
disease progression. Patients with more than 
100,000 copies/ml plasma within 6 months of 
seroconversion were 10 times more likely to 
progress to AIDS over 5 years than were those 
with fewer copies. Maintenance of <10,000 
copies/ml in early HIV infection is associated 
with a decreased risk of progression to AIDS. In 
contrast, in patients with more advanced 
disease, a low RNA count does not protect from 
progression; up to 30% of patients with <10,000 
copies/ml progressed (Coombs et al., 1996; 
Mellors et al., 1996; Saag et al., 1996; Welles et 
al., 1996; O'Brien et al., 1997). Patients with 
advanced disease can present with high or low 
viral RNA concentrations (Saag et al., 1996).  
RT-PCR, NASBA and bDNA methods are valid 
procedures for viral-load quantification, and the 
FDA-approved respective kits include the 
Amplicor HIV-1 Monitor Test version 1.5 
(Roche Diagnostic) with a detection limit of 50 
copies/ml; the NucliSens HIV-1 QT 
(bioMerieux) with a detection limit of 80 
copies/ml, and the VERSANT HIV-1RNA 3.0 
assay (Bayer) with a detection limit of 75 
copies/ml. The minimal change in viral load 
considered to be statistically significant (2 
standard deviations) is a threefold or a 0.5 log10 
copies/ml change. In the plasma of most 
untreated patients, viral RNA is detectable at all 
stages of disease. If RNA is undetectable in an 
untreated patient, this may reflect a very low 
viral load, as seen in long-term nonprogressors. 
However, the negative result may also be due to 
a virus not well recognized by the respective 
assay. The above-mentioned kits are not FDA 
approved for measuremtent of HIV-1 group O or 
HIV-2. Although underdetection of entire 
subtypes or clades by some tests meanwhile has 
been much improved, the current virus load kits 
may still exhibit weaknesses in detection of 
certain CRFs, or individual virus strains 
(Gueudin et al., 2007). This may also extend to 
subtype B viruses (author's unpublished 
observations). 
As a general rule, if quantitative tests of 
untreated patients yield an undetectable viral 
load, one should check the likelihood of an 
infection with an alternative subtype. This is 
particularly important in case of a low CD4+ T-
cell count or clinical events. A negative result in 
other virus component tests less affected by 
sequence variation supports a truly low load. 
Such alternative methods might also include the 
PERT assay, which, as a functional test for RT 
activity, is entirely independent of viral 
sequence and can therefore be used for 
quantification of HIV-1 subtype O or HIV-2 
(Bürgisser et al., 2000). Contrary to general 
perception, p24 antigen is also a valid 
prognostic marker when assessed by optimized 
procedures (Ledergerber et al., 2000; Sterling et 
al., 2002). Short-term changes in CD4+ T-cell 
counts in both adult and pediatric HIV-1 
infection correlated even better with the 
corresponding changes in concentration of HIV-
1 p24 than with those of HIV-1 RNA 
(Schupbach et al., 2005; Brinkhof et al., 2006).  
 
Antiretroviral Treatment and Its Monitoring 
Eradication of HIV infection cannot be achieved 
with available antiretroviral regimens. This is 
due to the pool of latently infected CD4+ T-cells 
that is established during early HIV infection 
and persists with a long half-life. Hence, the 
primary goals of therapy in HIV infected 
patients are to reduce HIV-related morbidity and 
mortality, to improve quality of life, to restore 
and preserve immunologic function, and to 
maximally and durably suppress viral load 
(Anonymous, 2006). Treatment with effective 
combinations of antiretroviral drugs has resulted 
in substantial reductions in HIV-related 
morbidity and mortality. Plasma viremia is a 
strong prognostic indicator of HIV disease 
progression. Reductions in plasma viremia 
achieved with such antiretroviral combination 
therapy account for substantial clinical benefits 
(O'Brien et al., 1996). Therefore, suppression of 
plasma viremia as much as possible for as long 
as possible is a critical goal of antiretroviral 
therapy.  
Due to the high variability of HIV and the 
generation of drug-resistant mutants, successful 
long-lasting suppression of virus replication can 
only be achieved with combination ART, 
frequently also called highly active anti-
retroviral therapy (HAART). Such regimens are 
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usually composed of at least three drugs selected 
from the groups of non-nucleoside RT inhibitors 
(NNRTI), protease inhibitors (PI), and 
nucleoside (or nucleotide) analogue RT 
inhibitors (NRTI). NRTIs function as 
nucleoside-triphophates for RT-mediated cDNA 
synthesis and act as chain terminators. NNRTI 
bind directly to the RT thereby blocking its 
active site either directly or indirectly. PIs block 
the active site of the viral PR, thereby inhibiting 
the processing of the Gag-Pol and Gag precursor 
proteins. More recently, entry and fusion 
inhibitors have become available, which block 
fusion-mediated virus entry into host cells. 
Investigational drug classes currently still in 
clinical evaluation include integrase inhibitors 
and co-receptor (CCR5, CXCR4) antagonists. 
For FDA-approved or investigational drugs and 
all questions regarding ART consult 
http://aidsinfo.nih.gov/.  
Treatment monitoring assesses the treatment-
induced reductions of the amounts of virus in 
the body. Effective ART decreases HIV-1 RNA 
concentrations in plasma by at least 1 log10 
within 8 weeks after start of treatment, to less 
than 400 copies/ml by 24 weeks and to less than 
50 copies/ml by 48 weeks. A virologic failure 
on treatment is present if these cornerstones are 
not met or if there is a repeated HIV RNA level 
above 400 copies/ml after prior suppression of 
viremia to lower than 400 copies/ml 
(Anonymous, 2006). 
The decrease in HIV RNA concentration in 
plasma is accompanied by a slow decrease in 
PBMC-associated proviral DNA. Analysis of 
lymphoid tissues shows, however, that virus-
expressing cells, not to mention provirus, are 
still detectable after years, and replication-
competent virus can also be isolated from 
lymphod tissues of such patients (Finzi et al., 
1997; Wong et al., 1997; Finzi et al., 1999). 
Interruption of the treatment regimen for brief 
periods may thus, within a few days, lead to 
reappearance of virus in plasma to levels seen 
prior to therapy (Neumann et al., 1999; Fischer 
et al., 2003).  
Concentrations of viral RNA in plasma are thus 
an imperfect reflection of the HIV situation in 
the lymphatics, which harbor 98% of the body's 
lymphocytes. The rapid decline of viral RNA 
levels in plasma of patients receiving HAART is 
nevertheless paralleled by a similar decline of 
viral RNA levels in the lymphatics (Cavert et 
al., 1997) and the gut-associated lymphoid 
tissue (Guadalupe et al., 2006; Poles et al., 
2006). In tonsil tissue there was a rapid drop in 
mononuclear cells acutely producing virus, with 
a half-life of 0.9 day, which is comparable to the 
1.1 days observed for acutely infected CD4+ T-
cells in the blood under similar treatment 
conditions. Viral RNA levels at the surface of 
follicular DC declined with an initial half-life of 
1.7 days followed by a slower decay with a half-
life of 14 days. Cell-associated viral RNA levels 
declined with a similar half-life. After 6 months, 
there were still infected cells and low levels of 
virus expression in the majority of patients 
(Cavert et al., 1997); cell-associated viral DNA 
and mRNA levels reached a plateau after about 
500 days of treatment, after which no further 
decrease was observed (Furtado et al., 1999). 
Ongoing low-level replication after more than 
18 months of aggressive treatment has been 
confirmed by the demonstration of unintegrated 
circular forms of viral DNA (Fig. 1C) or of 
sequence evolution (Chun et al., 1997; Furtado 
et al., 1999; Zhang et al., 1999).  
Viral load studies of patients receiving ART 
have so far focused on effects in plasma and the 
lymphatics. Little is known about the impact of 
these regimens on HIV infection of the CNS, 
and viral kinetics in the CNS have not been 
established.  
RNA-based tests are currently viewed as the 
only feasible methods of viral-load 
determination, and all treatment 
recommendations are based on HIV-1 RNA. 
Treatment monitoring based on real-time PERT 
assay, though not available commercially, 
would also be feasible, however, and is an 
excellent alternative to sequence-based tests 
(Bürgisser et al., 2000). In addition, the 
measurement of p24 antigen represents a 
valuable simple alternative for resource poor 
settings. In both adult and pediatric patients, 
HIV RNA and p24 behave similarly, in certain 
cases virtually identically (Boni et al., 1997; 
Nadal et al., 1999; Tehe et al., 2006). Similar to 
early PCR kits (Monitor HIV-1 RNA version 1) 
there is, however, underdetection of certain non-
B subtypes, while the sensitivity to subtype C is 
good (Knuchel et al., 2007). 
 
HIV Drug Resistance Testing 
The Achilles heel of any antimicrobial 
chemotherapy is the development of resistance. 
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Antiretroviral resistance develops when viral 
replication continues in the presence of the 
selective pressure of drug exposure. In the case 
of the antiretroviral drugs used against HIV, this 
is caused most frequently by mutations of the 
genes targeted by these drugs, namely, the genes 
coding for RT, PR, IN or gp41. Mutations 
conferring resistance may, however, also occur 
outside of the protein sequences targeted by 
antiretroviral drugs, as shown by certain 
mutations in the proteolytic processing sites 
encoded by the gag gene, which are targeted by 
the viral PR (Carrillo et al., 1998). Since many 
resistance mutations affect different drugs, 
resulting in cross-resistance, a detailed 
knowledge of these mutations is valuable for the 
design of treatment in individual patients. This 
is particularly true in view of the fact that 
viruses with resistance mutations may be 
transmitted and thus may be present in patients 
prior to any ART. The frequency of such 
transmissions in the U.S. and Western Europe is 
estimated at 10-15%; transmission of multidrug-
resistant viruses also has been observed 
(Weinstock et al., 2004; Descamps et al., 2005; 
Novak et al., 2005; Oette et al., 2006). 
There are two types of resistance mutations, 
primary and secondary. Primary mutations 
directly reduce the susceptibility of the virus to 
an antiretroviral drug, are relatively specific for 
each drug, and appear soon after treatment 
initiation. They permit the mutated virus to 
replicate in the presence of the drug, but its 
replicative capacity is usually impaired due to a 
decreased functional efficiency of the mutated 
enzyme or protein. When treatment with the 
failing drug is continued, virus strains with 
secondary mutations, which compensate for the 
impairment, will be selected over time. Most of 
these secondary (or compensatory) mutations do 
not further increase resistance to the drug but 
restore the replicative capacity of the mutant 
virus. While there is little overlap among 
primary mutations, many of the compensatory 
mutations are shared among drugs of the same 
family, NRTIs, NNRTIs, and PI. Failing drug 
regimens should therefore be switched as soon 
as they are recognized, in order to prevent 
secondary mutations (Anonymous, 2006).  
Not all apparent resistance to antiretroviral 
treatment is due to viral mutation and drug-
induced selection. Viruses of group O and HIV-
2 are intrinsically resistant to NNRTIs, since 
their RTs do not bind these drugs, which were 
developed based on the B subtype prevalent in 
industrialized countries (Parkin and Schapiro, 
2004). For some drugs, such as stavudine, 
cellular phosphokinases are needed to activate 
the drug to its triphosphate form intracellularly; 
previous treatment with zidovudine appears to 
decrease this enzyme activity, thus impairing the 
intracellular concentrations of active stavudine. 
Frequently, however, the reasons for a failing 
viral response to antiretroviral treatment are a 
lack of adherence to treatment, impaired 
intestinal drug absorbance, pharmacokinetic 
interactions, or continuing viral replication at 
sanctuary sites where drug concentrations are 
inadequate. These points should be evaluated 
before a resistance analysis is considered 
(Anonymous, 2006).  
Current guidelines issued in 2003 by the 
International AIDS Society-USA (IAS-USA) 
panel and in 2004 by a European panel 
recommend drug resistance testing in the setting 
in cases of acute or recent HIV infection, for 
patients who have been infected as long as 2 
years or more prior to initiating therapy, in cases 
of antiretroviral failure, and during pregnancy 
(Hirsch et al., 2003; Vandamme et al., 2004).  
The methods include genotypic and phenotypic 
assays (reviewed in Hirsch et al., 2003). 
Genotypic tests examine the population of viral 
genomes in a test sample for the presence of 
mutations known to confer resistance. More than 
100 resistance-associated mutations have been 
described. An updated list of HIV-1 resistance 
mutations is maintained by the IAS-USA Drug 
Resistance Mutations Group (Johnson et al., 
2006) and also accessible online 
(http://www.iasusa.org/resistance_mutations/). 
Phenotypic assays measure the degree of drug 
sensitivity of a population of viruses or the 
enzyme(s) targeted by the drug; the result of this 
assay is given as a 50 or 90% inhibitory 
concentration. Genotypic assays use RT-PCR to 
amplify the population of viral RNA sequences 
which code for the viral enzymes RT and PR, 
which are targeted by most of the currently 
available antiretroviral drugs. The analysis of the 
amplified sequences for known resistance 
mutations can then be done by various methods. 
One method uses reverse hybridization of the 
amplified material to sequence probes that are 
immobilized on a carrier surface. This principle 
is also used in the line probe assay, in which a 
limited number of mutations (a limitation which 
renders the test unsuitable for clinical practice 
(Garcia-Bujalance et al., 2005)) are assessed by 
hybridizing the amplified sequence to probes 
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that discriminate between wild-type and mutant 
sequences and are immobilized on a WB–like 
strip. On a more general scale, this principle is 
also utilized in chip-based high-density 
oligonucleotide arrays. Another frequently used 
method of product analysis is by automated 
sequence analysis of the target region.  
Phenotypic assays are performed with viruses 
isolated from patients and grown to sufficient 
quantity in a suitable target cell culture. To 
improve standardization, phenotypic resistance 
analysis also is performed by a recombinant-
virus approach. In this method, the respective 
target gene sequence is reverse transcribed from 
RNA that has been extracted from the patient's 
plasma, amplified, and inserted into a cloned 
defective virus backbone that lacks the 
sequences of interest. The reinsertion of these 
sequences renders the virus again competent for 
replication in a given cell line, and the 
recombinant viruses will exhibit standardized 
replication properties for all gene products 
except the inserted target gene sequences, which 
represent the patient's own virus population. 
A problem of all resistance assays is their 
limited capability to detect a minority of 
resistant mutants against a background of wild-
type sequences. Even under optimal conditions, 
resistant sequences usually need to be present in 
at least at 25-30% of the circulating virions in 
order to be reliably detected. Under practical 
conditions, as assessed in a round trial, in which 
panels with standardized mixtures of wild-type 
and mutant sequences of a cloned virus were 
assessed by genotyping laboratories around the 
world, results were far from optimal, indicating, 
as in the early days of PCR, the urgent need for 
standardization of these procedures and quality 
control (Schuurman et al., 1999). With these 
measures in place there is now both 
retrospective and prospective evidence in 
support of both clinical utility of resistance 
testing, especially when combined with expert 
interpretation (Deeks et al., 1999; Baxter et al., 
2000; Clevenbergh et al., 2002; Torre and 
Tambini, 2002; Ena et al., 2006) and cost 




HUMAN T-LYMPHOTROPIC VIRUSES (HTLV-1, HTLV-2, HTLV-3, HTLV-4) 
Biology  
Primate T-Lymphotropic Retroviruses (PTLV)  
The HTLV are members of the group of PTLV. 
Together with bovine leukemia virus, the PTLV 
form the genus deltaretrovirus in the 
orthoretrovirinae subfamily of the retroviridae.  
The first PTLVs identified were the human T-
lymphotropic viruses HTLV-1, discovered 
independently in the U.S. and Japan (Poiesz et 
al., 1981; Yoshida et al., 1982), and HTLV-2 
(Kalyanaraman et al., 1982). Subsequent 
investigations among nonhuman primates 
demonstrated related viruses in many different 
species of Old World monkeys. Phylogenetic 
analysis separated the PTLV into three different 
branches, PTLV-1, -2 and -3. Depending on 
whether PTLV are found in man or nonhuman 
primates, they are now named either HTLV-1, 
HTLV-2 or STLV-1, STLV-2, STLV-3. 
Hitherto unknown human viruses related to 
STLV-3 were recently identified in African 
hunters from Cameroon (HTLV-3), and a new 
human virus forming a fourth branch of PTLV, 
HTLV-4, was also identified (Calattini et al., 
2005; Wolfe et al., 2005; Calattini et al., 2006; 
Switzer et al., 2006). Fig. 9 summarizes the 
phylogenetic relationship of the PTLV. It 
documents that HTLV infection in man has 
resulted from multiple cross-species 
transmissions of STLV in the past. Such 
zoonotic transmission may well be ongoing. 
The finding of HTLVs in now four distinct 
clades suggests an ancient evolution. Molecular 
studies estimate the PTLV ancestor to have 
originated about 630,000 to 950,000 years ago, 
confirming an ancient evolution of primate 
deltaretroviruses (Salemi et al., 2000; Switzer et 
al., 2006). The separation of PTLV-1 and 
PTLV-2 occurred between 580,000 and 870,000 
years ago, while HTLV-2 and STLV-2 diverged 
around 190,000 to 290,000 years ago. The 
PTLV-3 progenitor was estimated to have 
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appeared between 63,000 and 95,000 years ago, 
with the ancestor of HTLV-3 occurring about 





FIGURE 9 Phylogenetic relationships of Primate T-Lymphotropic Retroviruses (PTLV) based on polymerase (pol; 662 bp). 
Sequences isolated from humans in the study by (Wolfe et al., 2005) are shown in boxes. Support for the branching order is based 
on 1,000 bootstrap replicates; only values of 60% or more are shown. Branch lengths are proportional to the evolutionary 
distance (scale bar) between the taxa. Taxa abbreviations are: Ppn, Pan paniscus (bonobo); Mto, Macaca tonkeana (Celebes 
macaque); Ppa, Papio papio (Guinea baboon); Cto, Cercocebus torquatus (red-capped mangabey); Tge, Theropitecus gelada 
(gelada baboon); Pha, Papio hamadryas (sacred baboon). Reprinted from the Proceedings of the National Academy of Sciences 
U.S.A. (Wolfe et al., 2005) with permission of the publisher. 
 
HTLV-1 comprizes different subtypes A-F. The 
cosmopolitan subtype A includes the prototype 
isolates from Japan and is found in many 
endemic areas worldwide. Its current worldwide 
distribution is thought to result from relatively 
recent human migration such as the European 
voyages of discovery of past centuries and the 
slave trade. Subtypes B, D and F are still 
restricted to Central Africa. Subtype E is 
prevalent in South and Central Africa and 
subtype C is found in Melanesia (Seiki et al., 
1982; Sherman et al., 1992; Gessain, 1996; 
Slattery et al., 1999).  
HTLV-2 comprises two main subtypes, A and B 
(Hall et al., 1992). Both are present in 
intravenous drug users in North America, 
Europe, and Asia and have been found 
sporadically in Africa. HTLV-2a is present in 
certain American Indian tribes of North, Central, 
and South America, including the Navajo and 
Pueblo in New Mexico and the Kayapo, Kraho, 
and Kaxuyana in Brazil. A subcluster of 
Brazilian Indian HTLV-2a strains has been 
proposed to represent a different subtype HTLV-
2c (Eiraku et al., 1996). Due to a high 
prevalence in isolated Amerindian populations, 
HTLV-2 was originally considered to be of New 
World origin. The discovery of endemic HTLV-
2 infections in remote Pygmy populations and 
the identification of a simian virus closely 
related to HTLV-2 in bonobos suggest, however, 
that HTLV-2 rather has its origin in Africa. The 
molecular characterization of an HTLV-2b 
isolate from a Cameroonian Pygmy and a 
Congolese Efe Pygmy HTLV-2 strain belonging 
to a potential new subtype, HTLV-2d, also 
support an ancient African origin of HTLV-2 
(Vandamme et al., 1998). 
  
 
FIGURE 10 HTLV-1 open reading frames (ORFs) and transcription map. A scheme of the HTLV-1 genome, alternatively 
spliced mRNAs, and putative proteins encoded by each mRNA is shown. ORFs are indicated by boxes. Nucleotide numbering 
starts from the first nucleotide in the mRNA. Reproduced from Oncogene (Nicot et al., 2005) with permission of the publisher. 
 
Genome, transcripts and viral proteins  
The HTLV genome contains downstream of the 
gag, pol and env genes an additional coding 
region called pX (Fig. 10). The pX region codes 
for regulatory and accessory genes in four open 
reading frames (pX ORFs I to IV). The 
regulatory proteins encoded by pX ORFs III and 
IV include p40-Tax and p27-Rex. These proteins 
have been characterized extensively.  
Tax (40 kd in HTLV-1and 37 kd in HTLV-2, 
respectively) is a potent trans-activator of HTLV 
expression (Kiyokawa et al., 1984; Sodroski et 
al., 1984). Tax does not bind to the LTR 
directly, but activates transcription by recruiting, 
or modifying the activity of, cellular 
transcription factors including cyclic AMP-
responsive element binding protein (CREB), 
serum-responsive factor (SRF) and NF-κB. 
Three highly conserved 21-bp repeat elements 
located within the long terminal repeat, 
commonly referred to as Tax-responsive element 
1 (TRE-1), are critical to Tax-mediated viral 
transcriptional activation through complex 
interactions with cellular transcription factors 
(Grassmann et al., 2005). Tax also has been 
shown to activate transcription from a large 
number of critical cellular genes through the NF-
κB and serum-responsive factor pathways 
(reviewed in Grassmann et al., 2005; Hall and 
Fujii, 2005; Kashanchi and Brady, 2005; Sun 
and Yamaoka, 2005). 
Rex (p27 for HTLV-1; p26 for HTLV-2), is a 
splicing suppressor of the viral transcripts 
functionally similar to HIV Rev (Seiki et al., 
1985). It recognizes a specific response element 
on incompletely spliced viral mRNAs, stabilizes 
them, inhibits their splicing and transports them 
to the cytoplasm. Rex is indispensable for 
efficient viral replication, infection and spread. It 
is considered to regulate the switch between 
latent and productive HTLV infection. Without 
Rex, the virus would still produce regulatory and 
some accessory proteins; however, structural and 
enzymatic post-transcriptional gene expression 
would be severely repressed, essentially leading 
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to a non-productive state of infection (reviewed 
by Younis and Green, 2005). 
The interplay of Tax and Rex leads to a 
sequential and, to some degree, transitory viral 
expression in infected cells (Seiki et al., 1988; 
Yoshida et al., 1989). As summarized in Fig. 11, 
an initial HTLV-1 transcript is fully spliced into 
a pX mRNA encoding for p40-Tax and p27-Rex. 
Tax trans-activates the transcription of the viral 
genome; thus viral expression is potently 
enhanced. Next, p27-Rex, which is encoded by 
the same pX mRNA species, accumulates and 
suppresses the splicing of the viral transcripts. 
As a consequence, unspliced gag-pol-env and 
singly spliced env mRNAs are expressed and 
viral structural proteins produced, while at the 
same time the level of fully spliced pX mRNA 
encoding for Tax decreases, thus resulting in 




FIGURE 11 Feed back regulation of HTLV-1 gene expression by Tax and Rex. Spontaneous viral expression of Tax from 
doubly spliced viral transcript. (1) Tax further activates subsequent viral transcription; (2) Rex encoded by the same mRNA as 
Tax suppresses splicing of viral RNA, (3) thus accumulation of unspliced mRNAs which express Gag, Pol and Env proteins on 
the one side, but down-regulation of Tax/Rex expression and shut-off of transcription on the other side. Reprinted from 
Oncogene (Yoshida, 2005) with permission of the publisher. 
 
Tax is a tumorigenic protein, as is shown by the 
induction of mesenchymal tumors in transgenic 
mice (Nerenberg et al., 1987). This finding 
implies that Tax is not only a potent activator for 
HTLV's own transcription, but must also act on 
cellular genes. Numerous investigations indeed 
have demonstrated that Tax influences the 
expression of many different cellular genes, and 
the initial steps in the pathogenesis of ATLL are 
firmly linked to the pleiotropic activity of Tax. 
In brief, and as described in detail in recent 
reviews (Neuveut and Jeang, 2002; Franchini et 
al., 2003; Jeang et al., 2004; Kehn et al., 2004; 
Kashanchi and Brady, 2005; Pise-Masison and 
Brady, 2005; Yoshida, 2005), Tax induces 
abnormal cell growth by activating growth-
promoting genes, by repressing growth 
suppressing genes and also by inhibiting tumor 
suppressor proteins. During abnormal cell 
proliferation, once thus induced, Tax also 
suppresses DNA repair capacity and bypasses 
the cell cycle checkpoint by inactivation of 
checkpoint function, thereby enhancing 
accumulation of mutations. Furthermore, Tax 
inhibits apoptotic cell death even in cells with 
abnormally damaged DNA. Over repeated cell 
cycles, some cells may fortuitiously accumulate 
a combination of DNA mutations, that trigger 
transformation and progress into malignant 
conversion. The pleiotropic effects of Tax are 
thus comparable to the many steps required for 
tumorigenesis in other cancers, which occur 
sequentially over time and at a low rate of 
incidence (Yoshida, 2005).  
In contrast to Tax and Rex, the contribution of 
the four accessory proteins p12(I), p27(I), 
p13(II), and p30(II) to viral replication and 
pathogenesis is still rather unclear. Although 
they are dispensable for replication in vitro, the 
finding of specific cytotoxic T-cells and 
antibodies in infected patients suggests that these 
proteins are expressed in vivo. Proviral clones 
mutated in either pX ORF I or II, while fully 
competent in cell culture, are severely limited in 
their replicative capacity in a rabbit model of 
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HTLV-1 infection. Emerging evidence indicates 
that the HTLV-1 accessory proteins are 
important for establishment of viral infectivity, 
enhance T lymphocyte activation, and 
potentially alter gene transcription and 
mitochondrial function (reviewed in Albrecht 
and Lairmore, 2002; Kehn et al., 2004; Nicot et 
al., 2005).  
 
Establishment and persistence of HTLV 
infection in the host 
HTLV-1-infected cells enter the human body via 
three major routes: mother-to-infant 
transmission (mainly through breast-feeding), 
sexual transmission, and parenteral transmission. 
Recipients of blood transfusions have a high 
probability of getting infected. In contrast, fresh 
frozen plasma from seropositive donors does not 
transmit HTLV-1 (Okochi et al., 1984). 
Similarly, killing live cells from mother's milk 
by freezing and thawing abolishes viral 
transmission (Ando et al., 2004). Virus 
transmission in vivo thus requires live infected 
cells. This is in accordance with the results of 
early in vitro experiments, which found cell-free 
infection ineffective (Yamamoto et al., 1982; 
Popovic et al., 1983). HTLV-1 can infect various 
cell types, including T-cells, B cells, bone 
marrow, cord blood, and synovial cells. Its 
receptor has been identified as the ubiquitous 
glucose transporter type 1 (GLUT1) (Manel et 
al., 2005). Efficient transmission necessites, as 
noted above, a direct intimate contact between 
infected and noninfected cells. This is a 
prerequisite for the formation of the so-called 
'virological synapse', by which a viral core 
complex containing the viral RNA is transfered 
into a new target cell (Igakura et al., 2003). 
Infectious propagation of HTLV-1 thus is highly 
efficient. It can be targeted on suitable cells and 
seems not to depend on released virions, which 
are highly susceptible to various ways of 
inactivation by the host's immune system.  
Compared to HIV, the replication characteristics 
of HTLV in vivo differ in several aspects. There 
is no primary HTLV infection with a high level 
of virions in plasma. HTLV plasma viremia is 
also absent at the later stages of infection. RT-
PCR for HTLV RNA in plasma is negative even 
in symptomatic patients. HTLV expression in 
vivo is also low and viral transcripts require 
PCR for detection. Only a small minority of 
cells, about 1/5000 PBMC, express mRNA, 
usually for Tax/Rex (Gessain et al., 1991). In 
contrast, the proviral load, i.e. the proportion of 
infected PBMC, can be extremely high, 
exceeding 30% of the PBMC, or 50% of the 
CD4+ T-cells, in some individuals. The presence 
of such high levels of HTLV-1 infected cells, 
apparently in the absence of virions, mRNA or 
viral protein in the majority of HTLV-1 infected 
individuals, initially led to the conclusion that 
the proviral load was maintained mainly by 
clonal expansion of infected cells (Wattel et al., 
1996). This conclusion was supported by the 
relative lack of sequence variation both within 
and between HTLV-1 isolates, which appeared 
to exclude a major role of the error-prone 
reverse transcriptase in maintaining the proviral 
load (Daenke et al., 1990).  
The discovery of chronically activated cytotoxic 
T lymphocyte (CTL) responses, particularly to 
Tax (Jacobson et al., 1990; Kannagi et al., 
1991), and a high titer of anti-HTLV-1 
antibodies often including IgM (Nagasato et al., 
1991) suggested, however, that in addition to the 
clonal expansion HTLV expression must be 
ongoing in chronically infected patients. 
Therefore, current models propose that during 
chronic infection there is persistent expression of 
HTLV enabling Tax-mediated stimulation of 
mitosis resulting in clonal expansion. At the 
same time, virus expression may also lead to 
new infection of neighboring cells, perhaps 
preferentially via the immunologically sheltered 
'virological synapses'. Overt expression and 
release of virions into the bloodstream may, 
however, be efficiently curtailed by Tax-specific 
CTL responses, as the expression of Tax occurs 
prior to that of virion proteins and particle 
release (Fig. 11). CTL response in turn is subject 
to host genetic polymorphism, mainly in HLA 
class 1. In Japan, HLA-A*02 and HLA-Cw*08 
were independently and significantly associated 
with a lower proviral load and a lower risk for 
HTLV-associated myelopathy/tropical spastic 
paraperasis (HAM/TSP) (reviewed by Bangham 
and Osame, 2005). Compared to asymptomatic 
carriers, significantly higher average 
concentrations of proviral DNA are found in 
ATLL, HAM/TSP, and other inflammatory 
HTLV-1 associated disease manifestations 
(Nagai et al., 1998; Manns et al., 1999b; 
Bangham, 2003b; Yakova et al., 2005; Silva et 
al., 2007). Proviral load in asymptomatic carriers 
correlates strongly with the presence of 
abnormal lymphocytes resembling malignant 
ATLL cells (Hisada et al., 1998) and was 
identified as a significant predictor of 
subsequent progression to ATLL (Okayama et 
al., 2004). Interestingly, there is also a strong 
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correlation between Strongyloides stercoralis 
infection and the provirus load, suggesting that 
strongyloidosis could promote oligoclonal 
proliferation and development of ATLL (Gabet 
et al., 2000). 
 
 
Table 3. Diseases associated with HTLV-1 infection. Reprinted from Oncogene (Proietti et al., 2005), with permission 
by the publisher 
 
Adult disease  Association 
Adult T-cell leukemia/lymphoma (ATLL) ++++ 
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) ++++ 
Uveitis (frequent in Japan) ++++ 
Infective dermatitis (rare) +++ 
Polymyositis, inclusion body myositis ++ 
HTLV-1-associated arthritis ++ 
Pulmonary infiltrative pneumonitis  ++ 
Sjögren’s syndrome  + 
 
Childhood disease  Association 
Infective dermatitis (frequent in Jamaica) ++++ 
Tropical spastic paraparesis/HTLV-1-associated myelopathy (rare) ++++ 
Adult T-cell leukemia/lymphoma (very rare)  ++++ 
Persistent lymphadenopathy + 
 
 
HTLV Associated Disease and Pathogenesis  
HTLV-1–Associated Diseases  
Most individuals infected with HTLV-1 remain 
disease-free carriers throughout their lifetime. In 
2-6% of infected individuals, however, chronic 
disease may develop, usually after a long 
incubation time. Three characteristic disease 
entities, ATLL, HAM/TSP, and HTLV-
associated uveitis (HAU) have been etiologically 
linked with HTLV-1 infection in adults. 
Syndromes found associated with HTLV-1 in 
children predominantly include infective 
dermatitis and HAM/TSP. Other manifestations 
less well linked with HTLV-1 infection include 
various inflammatory diseases like polymyositis, 
arthritis, infiltrative pneumonitis, Sjögren's 
syndrome and, in children, persistent 
lymphadenopathy (Table 3). A general 
susceptibility to infectious diseases is also 
frequent. 
 
Adult T-cell Leukemia/Lymphoma (ATLL) 
Three decades ago, ATLL was recognized as a 
new disease in Japan based on characteristic 
clinical features, origin of the patients from a 
distinct geographic region in the South of the 
country and a CD4+ T-cell phenotype of the 
leukemic cells (Takatsuki et al., 1977; Uchiyama 
et al., 1977). ATLL develops after a long latency 
in a small fraction (2-6% life-time risk) of 
HTLV-1 infected individuals that are normally 
infected shortly after birth (Tajima, 1990; 
Tajima and Cartier, 1995). The mean age at 
disease onset is in the fifth life decade and the 
male to female ratio is 1.4:1 (Uchiyama et al., 
1977; Tajima, 1990; Shimoyama, 1991). 
Recently however, acute-type ATLL was 
diagosed also in 3 out of 8 HTLV-1 seropositive 
carriers only 6, 9, and 25 months after start of 
immunosuppressive therapy given in 
conjunction with allogeneic liver transplantation 
(Kawano et al., 2006). ATLL is classified into 
four clinical types: acute, chronic, smoldering 
and lymphoma type. More than 50% are of the 
acute type, 20% of the lymphoma type, 20% of 
the chronic type and about 5% of the smoldering 
type (Yamaguchi et al., 1983; Kawano et al., 
1985; Shimoyama, 1991; Takatsuki et al., 1996; 
Yamaguchi and Watanabe, 2002). 
Acute ATLL characteristically presents with 
general malaise, fever, cough, dyspnea, 
abdominal fullness, thirst and drowsiness. The 
diagnosis is based on the following criteria: 1) 
Histologically and/or cytologically proven 
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lymphoid malignancy of T-cell type. 2) 
Abnormal T lymphocytes with deeply 
convoluted or lobulated nuclei also referred to as 
flower cells present in the peripheral blood (Fig. 
12), except in the lymphoma type. 3) Presence of 
HTLV-1 antibody in serum. 4) Demonstration of 
clonality of HTLV-1 proviral DNA in tumor 
cells, for example by Southern blot, which is a 
definite diagnosis of ATLL (Takatsuki et al., 
1977; Shimoyama, 1991; Yamaguchi and 
Watanabe, 2002). Chronic ATLL is 
characterized by milder signs and symptoms and 
a more protracted clinical course. Patients with 
smoldering ATLL have fewer leukemic cells in 
their blood and frequently present with skin 
lesions such as papules, nodules and erythema. 
Lymph node enlargement and splenomegaly in 
these patients are minimal and serum LDH is 
normal to slightly elevated (Yamaguchi et al., 
1983). In lymphoma type ATLL, the 
predominant finding is lymph node enlargement. 
Major complications of ATLL include 
hypercalcemia, which eventually develops in 
70% of the patients (Prager et al., 1994; Nosaka 
et al., 2002), and serious opportunistic infections 
by bacteria, fungi, protozoa and viruses. As in 
AIDS, Pneumocystis jiroveci pneumonia, 
Strongyloides stercoralis, aspergillosis or 
candidiasis, and cytomegalovirus pneumonia are 
common and contribute to the poor prognosis 
(Shimoyama, 1991; Carvalho and Da Fonseca 
Porto, 2004; Taylor and Matsuoka, 2005). In 
1991, the median survival time reported was 6 
months for the acute type, 10 months for the 
lymphoma type, and 2 years for the chronic type. 
The corresponding four-year survival rates were 
5% for the acute and lymphoma types, 27% for 
the chronic type and 63% for smoldering ATLL 
(Shimoyama, 1991). Little progress has been 
made since then, and the vast increase in 
knowledge of the molecular biology and 
oncogenesis of ATLL still awaits translation into 
clinical benefit (Yamada and Tomonaga, 2003). 
The pathogenesis of ATLL involves a number of 
factors and several disease steps (Fig. 13). After 
initial cell-to-cell transmission, HTLV-1 
propagates itself by both de novo infection and 
Tax-mediated clonal expansion and inhibited 
apoptosis of infected cells. Because the HTLV 
provirus integrates at random sites into the 
cellular DNA, individual infected clones can be 
detected by Southern blot, inverse PCR or, once 
an integration site has been identified, site-
specific PCR. During the first 3 to 5 years after 
seroconversion a greater number of clones with 
fewer infected cells is present than is found in 
long-term carriers (Tanaka et al., 2005). Thus, 
the clonal proliferations of HTLV-1-infected 
cells become persistent, and the same clones can 
be detected at different time points (Etoh et al., 
1997; Cavrois et al., 1998). As an example, an 
HAM/TSP patient developed lymphoma-type 
ATLL. The ATLL clone was identified in a 
blood sample obtained before the onset of 
ATLL, which showed that the same clone was 
already present during HAM/TSP (Tamiya et al., 
1995). Cell clones subsequently converting to 
malignant ATLL cells were also identified by 
inverse PCR in patients of a prospective study of 
HTLV. Such clonal proliferation is directly 
associated with the onset of ATLL (Okayama et 
al., 2004). These studies clearly illustrate that 
HTLV-1-infected clones can progress to a 
malignant state during the carrier state. 
 
 
FIGURE 12 Morphology of ATLL cells. Note the typical 
nulear indentations (flower cells). Reprinted with 
permission from Alfred C. Feller, Jacques Diebold. 
Histopathology of Nodal and Extranodal Non-Hodgkin's 
Lymphomas (Based on the WHO Classification). 3rd 
edition, Springer Verlag. 2004, p. 131. 
 
All along the carrier state, infected cells undergo 
selection by the host's immune system, in 
particular cell-mediated immunity (Bangham, 
2003a; Bangham, 2003b), the genetic and 
epigenetic environment of proviral integration 
sites that influences provirus expression, and 
other factors. Such selection results in fewer 
clones, which further expand and predominate in 
long-term carriers (oligoclonal phase). In 
leukemic cells, tax gene expression is frequently 
impaired by genetic and epigenetic mechanisms. 
The resulting loss of Tax expression enables 
ATLL cells to escape the host's antiviral 
defenses. On the other hand, ATLL cells must 
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have acquired the ability to proliferate without 
Tax by intracellular genetic and epigenetic 
changes (reviewed in Taylor and Matsuoka, 
2005). 
 
HTLV-1 associated inflammatory disorders 
HTLV-1 is associated with a number of 
inflammatory disorders in addition to ATLL 
(Table 3). In contrast to ATLL, which is thought 
to develop partially due to a lack or secondary 
deterioration of CTL functions against T-cells 
expressing HTLV-1, the HTLV-1 associated 
inflammatory disorders are increasingly viewed 
as resulting from tissue damage triggered by 
exaggerated HTLV-1 induced T-cell responses 
(Shimojima et al., 2004). 
 
HTLV-1–associated myelopathy/tropical spastic 
paraparesis (HAM/TSP)  
Following identification of HTLV-1 as the 
etiologic agent of ATLL, a serological 
association with HTLV-1 was independently 
reported for patients from the Caribbean who 
suffered from TSP and for patients from Japan 
who presented with a myelopathy (Gessain et 
al., 1985; Osame et al., 1986). Comparative 
studies subsequently demonstrated that the 
viruses found in these diseases were genetically 
indistinguishable from the HTLV-1 strains that 
cause ATLL (Yoshida et al., 1987). HAM/TSP 
and ATLL are seen together only rarely in the 
same patient (Bartholomew et al., 1986; Kawai 
et al., 1989).  
The life-time risk of developing HAM/TSP 
among seropositive individuals varies from less 
than 0.1% in Japan to 1.7-7% reported from 
Africa, the Caribbean, and the U.S. (reviewed by 
Taylor, 1998). The mean age at onset is in the 
forth decade of life and the male to female ratio 
is about 1:3. The incubation time extends from 
years to decades, but may occasionally be as 
short as 18 weeks (Osame et al., 1990). Disease 
onset is usually slow; patients often have had 
symptoms for years before the diagnosis is 
established.  
Revised diagnostic criteria based on a WHO 
definition for HAM/TSP were proposed recently 
(De Castro-Costa et al., 2006). A definite 
diagnosis of HAM/TSP thus requires (i) a non-
remitting progressive spastic paraparesis with 
sufficiently impaired gait to be perceived by the 
patient. Sensory symptoms or signs may or may 
not be present. When present, they remain subtle 
and without a clear-cut sensory level. Urinary 
and anal incontinence may or may not be 
present. (ii) Presence of HTLV-1 antibodies in 
serum and cerebrospinal fluid (CSF) confirmed 
by WB and/or a positive PCR for HTLV-1 in 
blood and/or CSF. (iii) Exclusion of a long list 
of other conditions that can resemble HAM/TSP 
comprising, for example, multiple sclerosis, 
Lyme disease, neurosyphilis or 
neurotuberculosis. Criteria for probable and 
possible HAM/TSP were also proposed. 
Pathological examination shows the most 
prominent changes in the thoracic spinal cord, 
with atrophy of the cord and thickening of the 
meninges. The primarily affected white matter 
shows inflammatory cell infiltrates which to a 
lesser degree also are seen in gray matter 
(Iwasaki, 1993). These inflammatory infiltrates 
are initially comprised of both CD8 and CD4+ 
T-cells, B cells, and foamy macrophages, but 
later in the disease CD8 T-cells predominate. 
Through this inflammatory process, myelin and 
axon loss eventually occurs, and the tissue is 
replaced by glial proliferation and fibrillary 
astrocytosis (Iwasaki, 1993; Abe et al., 1999; 
Jacobson, 2002; Grindstaff and Gruener, 2005). 
Similar changes are seen in the WKAH rat 
model after infection with HTLV-1 (Miyatake et 
al., 2006). 
The HTLV-1 proviral load in PBMC of 
HAM/TSP patients is high; provirus 
concentrations are 3-50 fold higher than in 
asymptomatic carriers (Kubota et al., 1993; 
Olindo et al., 2005). HAM/TSP prevalence rose 
exponentially with the log(proviral load) when 
the proviral load exceeded 1% of the PBMC 
(Nagai et al., 1998). A high ratio of proviral 
loads in CSF cells compared to PBMC, but not 
the absolute load in either compartment, was 
found associated with clinically progressive 
disease and recent onset of HAM/TSP 
(Takenouchi et al., 2003). Together these 
findings suggest that clinical progression of 
HAM/TSP is associated with increased 
proliferation in, or increased immigration of 
HTLV-1-infected lymphocytes into, the CNS. 
How the presence of HTLV-1 in the CNS leads 
to HAM/TSP is still unclear, however, and 
several models are proposed (reviewed by 
Jacobson, 2002; Bangham, 2003b; Araujo and 
Silva, 2006). One model centers around a CTL 
response to Tax expressing cells within the CNS, 
leading to co-activation of microglial cells and 
41 
release of cytokines like TNFα that are toxic to 
the myelin (bystander effects). An autoimmune 
mechanism induced by molecular mimicry 
between Tax and a neuron-specific autoantigen, 
the so-called heterogeneous nuclear ribonuclear 
protein A1 (hnRNP A1), and associated with 
detectable cross-reactive antibodies in 




FIGURE 13 Natural course from HTLV-1 infection to onset of ATLL. HTLV-1 is transmitted in a cell-to-cell fashion. After 
infection, HTLV-1 promotes clonal proliferation of infected cells by pleiotropic actions of Tax and other viral proteins. 
Proliferation of HTLV-1-infected cells is controlled by cytotoxic T-cells in vivo. After a long latent period, ATLL develops in 
about 5% of asymptomatic carriers. In ATLL, the expression of Tax is inactivated by several mechanisms, suggesting that Tax is 
no longer necessary in ATLL stage. Alternatively, alterations and errors in the host genome accumulate progressively during the 
latent period, finally leading to onset of ATLL. Reprinted from Oncogene (Taylor and Matsuoka, 2005) with permission of the 
publisher
 
HTLV-1–associated uveitis (HAU)  
In 1992, an uveitis of otherwise unexplained 
etiology in HTLV-1 infected patients was 
proposed as another disease entity (Mochizuki et 
al., 1992). HAU patients are of similar age as 
those with HAM/TSP. They present with a 
blurred vision of acute or subacute onset, 
preserved visual acuity in most instances, iritis, 
vitreous opacities, retinal vasculitis with 
exudates and hemorrhages (Takahashi et al., 
2000). The condition usually responds well to 
ocular or oral administration of corticosteroids, 
although recurrence is observed frequently.  
Proviral DNA of HTLV-1 is present in a high 
percentage of T lymphocytes isolated from the 
intraocular fluid, suggesting that the intraocular 
presence of HTLV-1 infected T lymphocytes is 
due to positive selection rather than coincidence. 
These T-cells are activated and release 
inflammatory cytokines deemed responsible for 
HAU since they can be abrogated by 
corticosteroid therapy (Sagawa et al., 1995). 
HAU frequently seems to be associated with a 
history of Graves' disease (Yamaguchi et al., 
1994; Watanabe et al., 1997; Sarui et al., 2002); 
the combination of the two diseases was 
associated with a significantly higher proviral 
load in PBMC. The proviral load also correlated 
with disease activity in terms of vitreous 




HTLV-1–associated arthritis  
A chronic arthritis in HTLV-1–infected 
individuals was first described in 1989 
(Nishioka et al., 1989). HTLV-1–specific 
antibodies can be shown in synovials fluids of 
the affected joints, and proviral DNA was 
demonstrated in synovial tissues and synovial 
fluid lymphocytes (Kitajima et al., 1991). Like 
HAM/TSP and HAU, HTLV-1–associated 
arthritis is associated with increased proviral 
DNA levels. Similar to HAU, an increased 
provirus load was found in the disease-affected 
tissue (synovial cells) compared to PBMC 
(Yakova et al., 2005). 
Evidence that the arthritis of HTLV-1 infected 
persons is not due to a mere coincidence with a 
disease frequent in most countries includes the 
demonstration that HTLV-1 env-pX transgenic 
mice or rats develop chronic inflammatory 
lesions with similarity to human rheumatoid 
arthritis (Iwakura et al., 1995; Abe et al., 2006). 
The majority of infiltrating T-cells in arthritic 
joints of env-pX rats were activated CD4+ T-
cells, and their transfer into the joints of wild-
type rats also induced arthritis. 
 
HTLV-1–associated bronchopneumopathy  
Pulmonary complications are more frequent in 
patients with ATL than in patients with other 
hematologic malignancies. They are present in 
more than 90% of the ATL patients and include, 
in addition to leukemic cell infiltration, a variety 
of opportunistic infections. Patients with 
inflammatory conditions like HAM/TSP, HAU 
or arthritis also have frequent pulmonary 
complications characterized by T-lymphocytic 
alveolitis in the absence of leukemic cells or 
opportunistic pathogens. A similar pulmonary 
involvement is also detectable in clinically 
asymptomatic carriers. Characteristically, 
respiratory symptoms and chest radiographic 
abnormalities are rare, although 60-80% have T-
lymphocytic bronchiolitis, alveolitis or 
interstitial pneumonia. Chronic sinusitis is also 
frequent, especially in patients with diffuse 
panbronchiolitis. Regarding pathogeneis, similar 
mechanisms as discussed for HAM/TSP are 
proposed, namely cytotoxic T-cell responses and 
an inflammatory effect exerted by cytokines 
released from activated cells (Sugimoto et al., 
1998; Seki et al., 2000). 
 
HTLV-1 associated infective dermatitis (IDH) 
HTLV-1 associated IDH is a recurrent, infective 
form of eczema first described in Jamaica in 
1966 (Sweet, 1966) and later linked to vertically 
transmitted HTLV-1 infection (La Grenade et 
al., 1998). The onset is generally after 18 months 
of life, and the disease rarely persists until 
adulthood. Infective dermatitis is a chronic, 
relapsing skin infection frequently involving 
staphylococci or streptococci. It always involves 
the scalp and may progress to HAM/TSP or 
ATL. Most cases of IDH were reported from 
Jamaica and Brazil. Smaller case series were 
described in Trinidad and Tobago, Peru and 
Senegal. Curiously, in Japan, where the 
prevalence of HTLV-I infection is elevated, only 
two cases of children with IDH have been 
reported, both of which progressed to ATL in 
adulthood (Bittencourt et al., 2006). 
 
Unproven disease associations of HTLV  
A large study of the most common 
hematological diseases in Europe (n=730 plus 
210 controls) reported HTLV-1 infection in 
11/67 (17%) patients with a myelodysplastic 
syndrome (a neoplasia of myeloid cells), 1/26 
patients with T-cell non-Hodgkin lymphoma and 
1/1 patient with T-cell acute lymphocytic 
leukemia (Karlic et al., 1997), but these findings, 
in particular regarding the myelodysplastic 
syndrome, remain unconfirmed (Morselli et al., 
1999). Claims that cutaneous T-cell lymphomas 
are associated with an isolated presence of the 
HTLV-1 tax gene in the absence of antibodies to 
structural proteins (Manca et al., 1994; Pancake 
et al., 1995; Pancake et al., 1996) were not 
confirmed by other groups, even when 
cutaneous T-cell lymphomas patients from 
regions endemic for HTLV-1 or from the same 
country from which such reports originated were 
analyzed (Boni et al., 1996b; Bazarbachi et al., 
1997; Kikuchi et al., 1997; Wood et al., 1997). 
Reports of an isolated presence of sequences 
related to HTLV-1 tax continue, however, also 
in association with autoimmune disorders 
(Zucker-Franklin et al., 2000; Zucker-Franklin, 
2001; Manca et al., 2002; Morozov et al., 2002; 






HTLV-2 was originally isolated from a T-cell 
line (Mo-T) derived from a patient with a T-cell 
variant of hairy cell leukemia (Kalyanaraman et 
al., 1982). Subsequently, the virus was also 
isolated from a similar case which upon closer 
examination demonstrated a coexistence of two 
different proliferative processes, namely a CD8+ 
T-cell leukemia with monoclonally integrated 
HTLV-2 and a B-cell hairy cell leukemia which 
was negative for integrated HTLV-2 (Rosenblatt 
et al., 1986).  
A pathogenetic role of HTLV-2 in malignancies 
involving CD8+ T-cells was supported by the 
virus' tropism for CD8+ T-cells in vitro (Ijichi et 
al., 1992) and the fact that lymphocytes of 
HTLV-2 infected patients proliferate in vitro in 
the absence of antigenic stimulation, similar to 
cells of HTLV-1 infected individuals (Wiktor et 
al., 1991). Epidemiological studies have, 
however, excluded that the typical B-cell form 
of hairy cell leukemia is associated with HTLV-
2 (Hjelle et al., 1991). There is also no further 
evidence supporting a significant role of HTLV-
2 in causing lymphoproliferative diseases. Some 
evidence links HTLV-2 with HAM/TSP and 
perhaps with other neurological syndromes 
(Jacobson et al., 1993; Lehky et al., 1996; 
Murphy, 1996). It also appears to be associated 
with an increased incidence of pneumonia and 
bronchitis, inflammatory conditions such as 
arthritis and, perhaps, with an increased 
mortality (Murphy, 1996; Roucoux and Murphy, 
2004; Jarvis et al., 2005). In general, HTLV-2 
pathogenicity is lower than that of HTLV-1 
(Feuer and Green, 2005), which may be due to a 
lower proviral load (Hisada et al., 2005). The 
generally lower proviral load may be associated 
with a comparatively lower efficiency of Tax-2 
for viral transactivation, cellular transformation, 
induction of cell cycle arrest and suppression of 




FIGURE 14 Epidemiologic map of HTLV-1. Countries with a prevalence between 1 and 5% in some populations, are shown 
darkly shaded. Countries with a prevalence of less than 1% in some groups, due mainly to immigration from endemic areas, are 
shown in light shade. Note that HTLV-1 endemic areas do not correspond exactly to the country boundaries shown in the map. 
For example, HTLV-1 in Brazil, Japan and Iran is limited to distinct areas within each country. Reprinted from Oncogene 
(Proietti et al., 2005) with permission of the publisher. 
 
Epidemiology and Transmission of the 
HTLVs 
Foci of HTLV-1 infection are found 
geographically clustered, amounting to about 20 
million infected individuals worldwide (Proietti 
et al., 2005). The geographic distribution of the 
virus has been defined, with Japan, Africa, the 
Caribbean islands and South America as the 
areas of highest prevalence. Additional endemic 
regions include the Middle East, the Pacific 
Melanesian islands and Papua New Guinea (Fig. 
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14). HTLV-2 is endemic in Amerindian and 
pygmy tribes. More recently, injecting drug 
users in the U.S. and Europe have become 
infected with HTLV-1 and HTLV-2, particularly 
subtype A, and secondary sexual transmission 
has introduced the viruses at low levels into the 
general population and blood donors (Gessain 
and de The, 1996; Manns et al., 1999a; Roucoux 
and Murphy, 2004; Taylor et al., 2005). 
Like the HIVs, the HTLVs are transmitted by 
hetero- or homosexual intercourse, from mother-
to-child or by parenteral inoculation. Live 
HTLV-infected cells are essential in all 
transmission modes. Mother-to-child 
transmission is with 15-30% of similar 
frequency as in untreated HIV-1 infection and 
occurs predominately in the postnatal period 
through breast milk. Breast-milk transmission 
seems to be more efficient than for HIV-1 and 
occurs with a time- or dose-dependent 
frequency. In one study, overall transmission 
was 16%. It was 5% among infants breast-fed 
for up to three months and 27% among those 
breast-fed for over three months. Of 78 bottle-
fed infants 13% turned out to be infected, 
suggesting also connatal transmission (Hirata et 
al., 1992). In other studies, however, connatal 
transmission was considerably less frequent 
(3%). Although HTLV-1 infected cells were 
detected by PCR in 2.5% of the cord bloods 
from HTLV-1–positive pregnancies, this was not 
associated with infection when the babies were 
formula-fed (Hino et al., 1996). In high-
prevalence areas, serologic testing of pregnant 
women and counseling of those found infected 
with regard to alternatives to breast-feeding is 
thus recommended. Transmission by breast-milk 
also depends on its provirus load (Ureta-Vidal et 
al., 1999; Li et al., 2004). 
Transmission by blood products is, in contrast to 
HIV, strictly cell-associated; the virus is not 
transmitted by plasma or plasma-derived 
products (Okochi et al., 1984). Recipients of 
contaminated blood seroconvert with a 40–60% 
probability and a median seroconversion time 
estimated at 51 days (Manns et al., 1999a). 
HTLV screening of blood donors is justified in 




Diagnosis of HTLV Infections 
The principles, tools and problems of HTLV 
diagnosis are, with some modifications, the same 
as those for the diagnosis of HIV (see above). 
Screening is based on tests for HTLV-specific 
antibodies by ELISA or particle agglutination 
tests. Confirmatory tests are based on WB or 
LIA. Since there are many indeterminate WB 
results, confirmation must be backed by 
supplemental tests, usually PCR for proviral 
DNA. Tests for virion components (antigen, 
viral RNA) in plasma are not to be used, as there 
is no HTLV plasma viremia.  
 
Screening Tests for HTLV-1/2 
For HTLV-1/2 screening, tests analogous to 
those reviewed in Fig. 6 for the detection of HIV 
are used, with the same principal advantages and 
drawbacks. Since all subtypes of HTLV-1 
diverge less than 10% from each other, 
underdetection of HTLV-1 infection as a result 
of sequence diversity is not a problem. 
Similarly, some sequences like the capsid region 
of gag, are also well conserved between HTLV-
1 and HTLV-2, and there is broad serologic 
crossreactivity between the two virus types. Due 
to the low degree of provirus expression and the 
presumed rapid CTL-mediated elimination of 
Tax-expressing cells, antibody levels to 
structural proteins may be low, however. Thus, 
third generation tests (double antigen sandwich 
EIA or particle agglutination) are the preferred 
test formats, as they should provide the highest 
sensitivity. Tests based on ELISA, particle 
agglutination or indirect immune fluorescence 
are available from various companies (Taylor et 
al., 1996; Farias de Carvalho et al., 1997; 
Vrielink et al., 1999; Boni et al., 2004a). For 
FDA-approved tests refer to 
http://www.fda.gov/cber/products/testkits.htm. 
Note that there are considerable differences in 
the quality of these products, particularly 
regarding specificity. In low-prevalence 
populations, a reactive result in an assay of low 
specificity has a very low positive predictive 
value (PPV). For example, one recent study 
involving four different HTLV-1/2 EIAs found a 
specificity above 99% in three of the tests, but of 
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only 93% in the fourth test. Even among a high-
risk group with a prevalence of 311/100,000, the 
PPV varied from an unacceptably low 4% (for 
the test with 93% specificity) to a maximum of 
44% for a test with 99.6% specificity. Provided 
that these assays exhibited the same specificity 
among blood donors (in whom the prevalence 
was 0.08/100,000), these PPV would indicate 
that with the most specific assay only 2/10,000 
reactive results would indicate a true infection. 
In contrast, with the least specific assay only 
1/100,000 reactive results would indicate a true 
infection. These data illustrate the need for both 
a careful choice of screening assays and of 
supplementary testing (Petersen et al., 1994; 
Boni et al., 2004a). 
 
Supplemental Tests for HTLV-1/2 
Western blotting and line immunoassay  
Serologic confirmation of HTLV-1/2 infection 
requires the demonstration of antibodies to both 
gag (p24) and env (gp46 and/or gp68 proteins) 
by WB and/or radioimmunoprecipitation assay 
(Anonymous, 1993). In our view, WB is 
preferable to in-house methods of confirmation 
like radioimmunoprecipitation assay, since the 
commercial WB kits are better standardized and 
much easier to run. WB kits are provided by a 
number of companies. Of particular interest are 
strips which contain, in addition to the viral 
proteins derived from viral lysate, recombinant 
proteins representing TM of HTLV-1 (which 
due to a high homology is also detected by 
antibodies from individuals infected with 
HTLV-2) and type-specific SU (gp46) of 
HTLV-1 and HTLV-2. This increases the 
sensitivity since the concentration of the gp46 
for HTLV-1 and gp68 for HTLV-2Env proteins 
on the strips is usually low in kits derived from 
lysate alone. Based on the pattern of the 
reactivity it is frequently, though not always, 
possible to decide whether infection by HTLV-1 
or HTLV-2 is present. With such strips, intense 
reaction with the gag proteins p19 and p24 and 
the env recombinant proteins rgp21 and rgp46 of 
HTLV-1 satisfies positivity for HTLV-1 and 
intense reaction with p24, rgp21 and rgp46 of 
HTLV-2 satisfies positivity for HTLV-2 
(Medrano et al., 1997).  
Furthermore, the use of LIA strips, which 
contain standardized concentrations of 
recombinant proteins and/or synthetic peptides 
of HTLV-1 and/or HTLV-2 at defined positions 
and thus can be considered as a kind of 2nd 
generation WB, presents advantages with respect 
to both sensitivity and specificity (Zrein et al., 
1998; Sabino et al., 1999; Thorstensson et al., 
2002).  
Still, in many cases WB and LIA do not permit 
an unequivocal diagnosis, owing to a high 
percentage of samples with indeterminate 
results. There is nonspecific reaction not only 
with lysate-derived natural gag proteins, but also 
with recombinant env proteins (Table 4). Some 
of these indeterminates may have very intense 
reactions with p19 or p24 and a variety of larger 
proteins such as p26, p28, p32, p36, p45 and 
p53. These proteins are present in HTLV-1 
infected cells and contain either a p19 or p24 
moiety, or both (Schupbach and Kalyanaraman, 
1989). Reaction with several of these gag 
proteins on a WB thus may signify no more than 
reaction with a single epitope of p19 or, 
respectively, p24 (Schupbach et al., 1988). 
Sometimes, intense gag patterns may also be 
combined with weak reaction to envelope rgp21 
and/or rgp46I or rgp46II, but even this does not 
necessarily imply HTLV infection. Weak 
reactions with recombinant envelope proteins in 
all possible combinations may also be found in 
the absence of reaction with gag proteins. In 
many instances, confirmation by PCR is thus 
necessary. This is particulary true for areas or 
populations in which HTLVs are not endemic. 
Under such conditions, any suggestive 
serological result not strongly antibody-positive 
should be confirmed by PCR. Indeterminate 
reactions are frequent in populations at risk for 
exposure, as drug addicts (Medrano et al., 1997), 
but may also be present in truly infected 
individuals (Zehender et al., 1996; Caterino-de-
Araujo et al., 1998). Infection with the SARS 
coronavirus has recently been identified as a 
possible cause of false reactivity in both HTLV 
screening tests and WB (Tsao et al., 2005). 
Given the problems with nonspecific bands in 
WB alternative diagnostic strategies based on 
testing with a combination of two sensitive and 
specific EIAs have been proposed (Thorstensson 
et al., 2002). Thus, while maintaining a higher 
overall sensitivity than with the classical EIA-
WB combination, an EIA-EIA strategy reduced 
the frequency of samples with indeterminate 




Polymerase chain reaction (PCR)  
PCR analysis for HTLV-1 and/or HTLV-2 DNA 
is necessary for all serologically indeterminates 
in which antibody reaction to Env proteins 
(rgp21, rgp46I or rgp46II) is present. Antibody 
reaction with Gag proteins p19 and/or p24 alone, 
or rgp21 alone, has been found by PCR not to be 
associated with HTLV infection (Defer et al., 
1995). PCR is performed on Ficoll-purified 
PBMC and frequently uses a sequence of tax 
which is conserved for both HTLV-1 and 
HTLV-2 and amplified by primers designated 
SK43/SK44, while the product is detected by 
probe SK45 (Kwok et al., 1988; Kwok et al., 
1990). Differentiation of HTLV-1 and HTLV-2 
in samples positive in this initial "screening 
PCR" is then achieved by amplification of a 
type-specific region in pol. Primers SK110 and 
SK111 in combination with probe SK112 are 
used for detection of HTLV-1. The same primers 
in combination with probe SK188 are employed 
for HTLV-2. This system also is available as a 
commercial kit (Amplicor HTLV 1-2 PCR test, 
Roche Diagnostic Systems)(Vrielink et al., 
1997). Alternatively, in-house PCR methods 
described by various authors can be used for 
both the screening step and the type 
differentiation (Vandamme et al., 1997; Salemi 
et al., 1998; Boni et al., 2004a). Real-time PCR 
methods also have been described (Davidson et 
al., 2006). 
 
Table 4: Breakdown of procedures undertaken in a reference lab during repeat testing of HIV-positive samples with 
additional reactivity or high-negative results in HTLV-1/2 ELISA screening. Reprinted from Journal of Medical Virology 
(Boni et al., 2004a) with permission of the publisher.     

























1 IDU PL 25.77 +++ +++ - ++ - +++ +++ +++ - +++ +    HTLV-2 
2 IDU PL 8.09 ++ +++ - + - ++ + +++ - +++ +    HTLV-2 
3 HET CR 7.76 +++ +++ +++ +++ - - - +++ +++ - +    HTLV-1 
4 HET PL 7.37 +++ +++ - ++ - ++ ++ +++ - +++ +    HTLV-2 
5 IDU CR 6.16 +++ - - - - - - +++ - +++ + + +,+ -,- HTLV-2 
6 IDU PL 3.34 ++ +++ - + - ++ + +++ - +++ +    HTLV-2 
7 IDU AB 2.47 - - - - - - - - - + - -,- -,- -,- neg 
8 IDU AB 1.93 - ++ - - - - - +++ - +++ - -,- -,- -,- neg 
9 IDU CR 1.50 - - - - - - - ++ - - - - - + neg 
10 HET AB 1.35 - - - - - - - - + - - -,- -,- -,- neg 
11 HET AB 1.34 - - - - - - - + - - - -,- -,- -,- neg 
12 HET AB 1.30 - - - - - - - - - + - - - + neg 
13 IDU AB 1.26 - - - - - - - - ++ - - - - - neg 
14 MSM AB 1.25 - - - - - - - - + + - -,- - - neg 
15 HET AB 1.13 - ++ - - - - - - - - - - - - neg 
16 MSM AB 1.11 +++ - ++ - ++ - - - - +     neg 
17 IDU AB 1.07 - + - - - - - - - - - - - + neg 
18 IDU AB 1.06 - + - - - - - - - - - - - - neg 
19 IDU AB 1.01 - - - - - - - - + - - - - - neg 
20 HET AB 0.87 - - - - +++ - - - - - - -,- - - neg 
21 HET AB 0.86 +++ - ++ ++ - ++ - - - - - -,- - - neg 
22 IDU AB 0.83 - - - - - - - ++ + + - - nd nd neg 
1 MSM = homosexual contact; HET = heterosexual contact; IDU = intravenous drug use. 
2 PL = Platelia (Bio-Rad); CR = Cobas (Roche); AB = Abbott HTLV-I/II EIA 
3 HTLV BLOT Version 2.4 (Genelabs Diagnostics, Inc). NB: Reaction intensities were subjectively rated as ‘no 
reaction’ (-); ‘clearly visible, but weak’ (+); ‘intermediately strong’ (++); ‘strong’ (+++). Reactions with natural proteins 
p21E and gp46E were all negative and are not listed. 
4 Symbols summarize results for supernatants sampled twice per week for at least 2 weeks. Symbols separated by a 
comma represent results of duplicate cultures. 
 
 
Virus isolation  
Compared with PCR virus isolation is time-
consuming and overall more expensive and 
therefore has little use for mere confirmation 
of HTLV infection. The procedure is, however, 
still justified as a research tool for detecting 
unknown retroviruses, that might eventually 
explain some of the numerous indeterminate 
serologic results (Boni et al., 2004a). Virus 
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isolation should thus not only be evaluated 
with HTLV-specific tests, (antigen assay or 
immunofluerescence), but where available also 
by assays for particle-associated reverse 
transcriptase, preferentially PERT assay (see 
"Supplemental testing - virus components" in 
the section on HIV). For virus isolation, 
Ficoll-purified PBMC are cocultured with 
phytohemagglutinin-preactivated normal 
PBMC or cord blood leukocytes in an IL-2 
containing medium. Supernatant is analyzed 
twice weekly for RT. In case of HTLV 
infection the PERT assay usually becomes 
positive within a few days, while detection of 
RT by convential assays may take several 
weeks. When the PERT assay has become 
positive, specific tests for HTLV like p24 
antigen assay, PCR or RT-PCR can be 
performed. Differentiation of HTLV-1 and 
HTLV-2 in virus culture is best achieved by 
PCR. The use of generic PCR primers and 
specific probes capable of differentiating 
between the various primate T-lymphotropic 
retroviruses is helpful in such a situation 
(Vandamme et al., 1997).  
 
Disease monitoring by provirus quantification 
As a high HTLV-1 provirus concentration is 
associated with the development of various 
HTLV-associated illnesses and the 
transmission risk by breast milk (Li et al., 
2004), measurement of the HTLV-1 provirus 
load is often required, although it has not yet 
been as firmly established for disease 
monitoring as is the case with the HIV-1 
virion load. Most ATLL cells contain only one 
provirus copy. As ATLL cells are derived 
from HTLV-1 infected cells, it is reasonable to 
conclude that most HTLV-1 infected cells 
contain also only one provirus. Provirus 
quantification by quantitative PCR thus can be 
used for enumeration of HTLV-1 infected 
cells in vivo. HTLV-1 provirus load in 
infected individuals differs more than 1000-
fold among asymptomatic carriers (Etoh et al., 
1999).  
 
Treatment of HTLV Infection 
During the three decades that have passed 
since the recognition of ATLL a variety of 
treatment approaches has been evaluated 
(reviewed by Taylor and Matsuoka, 2005). 
Combination chemotherapy with 
cyclosphosphamide, adriamycin, vincristine and 
prednisolone (CHOP) is still the standard first-line 
therapy. Many patients experience either partial or 
complete remission, but its duration is usually 
short, and the median survival time is only 6 
months. Intensification of CHOP with etoposide, 
vindesine, ranimustine, and mitoxantrone was 
associated with a higher remission rate, but 
median survival increased only insignificantly. 
The best outcome of combination chemotherapy, 
with a median survival time of 13 months, was 
achieved with an aggressive multidrug approach 
of high bone marrow toxicity given in 
combination with granulocyte monocyte – colony 
stimulating factor (Yamada et al., 2001). Overall, 
ATLL survival with various chemotherapy 
regimens remains poor, with survival in several 
cohorts of patients presenting prodominantly with 
acute leukemia or lymphoma ranging between 5.5 
and 13 months. Supplementation of chemotherapy 
with interferon-alpha and zidovudine as first line 
therapy yielded a median survival time of 18 
months (Matutes et al., 2001; Kchour et al., 2007). 
Since ATLL is a monoclonal disease which does 
no longer depend on viral replication, it is unlikely 
that the effect of zidovudin is based on inhibition 
of RT; an antineoplastic mechanism is more likely 
. Of interest are also drugs that appear to induce 
apoptosis of ATLL cells, like the combination of 
IFNα and arsensic trioxide (Mahieux and 
Hermine, 2005; Heraud et al., 2006), blockers of 
NF-κB, and histone deacetylation inhibitors 
(HDIs) like sodium valproate. Sodium valproate is 
a drug widely prescribed for epilepsy, bipolar 
disorders and migraine and has an excellent safety 
record. Of interest is that dramatic clearance of 
both lymphoma and leukemia has been 
demonstrated in a B-cell malignancy of sheep, that 
is induced by bovine leukemia virus, which is a 
close relative of HTLV. It is hypothesized that 
inhibition of DNA deacetylation leads to better 
provirus expression, thereby resulting in improved 
immune-mediated elimination of virus-expressing 
leukemic cells (Achachi et al., 2005). Valproate is 
also of potential interest for prevention of 
progression to acute ATLL in patients with the 
smoldering or chronic forms of ATLL, or for 
carriers still asymptomatic with a high proviral 
load, who are at risk for development of disease. 
A variety of monoclonal antibodies also has been 
evaluated.  
ATLL cells exhibit a high density of the IL-2 
receptor alpha chain (CD25), and treatment with 
CD25-specific mAb was capable of inducing 
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remission in a minority of the patients 
(Waldmann et al., 1988). CD25-specific mAb, 
meanwhile in humanized form, are also tried 
in combination with CHOP. Another target of 
mAb therapy is CD52. A humanized mAb to 
CD52, Campath-1H, was shown to effectively 
treat severe combined immunodeficiency mice 
inoculated with tumor-causing human ATLL 
cells (Zhang et al., 2003) and showed promise 
in human patients (Mone et al., 2005).  
Finally, both allogeneic and autologous bone 
marrow transplantation are evaluated as 
possible treatments of ATLL. A first case of 
apparent cure was reported in 1996. After a 4-
day infusion of cyclophosphamide, etoposide 
and doxorubicin, the patient was grafted with 
bone marrow cells donated by an HTLV-
uninfected sister (Borg et al., 1996). Nine 
years later, in 2005, the patient was still alive 
and free of disease. In a case series of 10 
patients receiving allogeneic hematopoietic 
stem cell therapy (Allo-SCT) (9/10 from 
HLA-identical siblings) after receiving total 
body irradiation and other conditioning agents, 
the median leukemia-free survival time was 
>17.5 months. Four patients died, however, 
and in two others ATLL relapsed (Utsunomiya 
et al., 2001). Further experience with this 
treatment in 40 patients shows that complete 
remission is achieved in a high proportion of 
patients. However, there is also a high rate of 
transplantation-associated complications 
resulting in an overall median survival of less 
than 10 months (Fukushima et al., 2005). 
Overall, ATLL remains a disease of poor 
prognosis. Prevention of the disease is thus of 
paramount importance. Public health 
intervention with the aim to provide education 
and counseling of high-risk individuals and 
populations is required. Avoidance of breast 
feeding and the introduction of HTLV 
screening of all blood donors have led to a 
significant decline of the carrier rate among 
the younger generation in Japan (Takatsuki et 
al., 1996). Given the high kit costs for blood 
donor screening, a transfer of this strategy to 
resource poor settings with HTLV-1 
endemicity has so far not been possible. Blood 
transfusion still represents a risk of HTLV-1 
infection for recipients in most African 
countries, as well as for other less developed 
areas (Mbanya et al., 2003). Prevention of 
mother to child transmission would likely have 
a significant impact on the incidence of 
HTLV-1-associated diseases, but the benefits 
of avoiding breastfeeding must be weighed against 
its risks, namely malnutrition and increased infant 
mortality. Recommendations to prevent sexually 
transmitted infections are the same as for the 
prevention of HIV infection. 
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